Random heteropolymer excipients for high protein concentration formulations
By using polymer excipients in high molecular weight random polymer library, the high viscosity and easy precipitation of high-concentration protein preparations are solved, their stability and application safety are improved, and effective stability under different conditions are achieved sex.
Patent Information
- Application Number
- CN202380024985.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-08
- Filing Date
- 2023-03-06
- Publication Date
- 2024-11-08
AI Technical Summary
Existing high-concentration protein preparations limit the type of manufacture and application due to their high viscosity and easy precipitation. Traditional small-molecule excipients are ineffective and unsafe for all proteins and may diffuse during dilution or in vivo administration, reducing stability. .
Using random polymer libraries with higher molecular weight than traditional small molecule protein preparations, including mixtures of various monomers such as methyl methacrylate, oligo(ethylene glycol) methyl ether methacrylate and isobutyl methacrylate. , by controlling the molecular weight and monomer ratio of the polymer, a polymer excipient with a molecular weight of more than 10 times is formed to stabilize the high concentration of protein preparation, reduce viscosity and inhibit precipitation.
It effectively reduces the viscosity of high-concentration protein preparations, improves its stability and manufacturing convenience, and ensures safety and shelf life under different application methods.
Smart Images

Figure BDA0005022555950000021 
Figure BDA0005022555950000051 
Figure BDA0005022555950000052
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Application No. 63 / 317,648, filed on March 8, 2022, the entire contents of which are incorporated herein by reference for all purposes. Technical Field
[0003] The present application relates to random polymer libraries and specific polymers that can be used, for example, to stabilize high concentration protein compositions, such as high concentration antibody compositions. Background Art
[0004] Many protein compositions, such as pharmaceutical preparations, contain relatively low concentrations of protein active ingredients, which can limit the utility of those compositions, for example, by limiting the modes of administration of these compositions. For example, many protein therapeutics must be administered intravenously in large volumes of solution because these therapeutics cannot be sufficiently concentrated for other modes of administration that require smaller volumes of administration, such as subcutaneous injection, intravitreal injection, intraocular administration, intranasal administration, inhalation, topical administration, and other methods. Therefore, there is a continuing need for methods of stabilizing protein-containing compositions at high concentrations that allow the compositions to have adequate shelf life and are also operable and safe for therapeutic use.
[0005] Some high-concentration protein formulations, even if relatively stable, may still have high viscosity, for example, which limits their manufacturability and application types. Certain small molecule excipients (such as arginine and other amino acids) may reduce viscosity based on specific circumstances, depending on the protein in question, but are not effective for all proteins. In addition, such excipients are not safe for all therapeutic administration modes, and in some cases may not be sufficient to stabilize the protein during storage or when applied. Small molecule excipients, such as amino acids, may also diffuse out of the protein material when applying or diluting the protein formulation, which may reduce the stability of the protein. Therefore, new methods are needed to help reduce the viscosity of high-concentration protein formulations. In addition, it is necessary to identify new excipients that may help limit the precipitation of protein formulations and / or diffuse out of the protein as quickly as small molecule excipients when diluted or applied in vivo. Summary of the invention
[0006] The present disclosure particularly describes polymers with higher molecular weights than traditional small molecule protein formulation stabilizers such as amino acids and sugars and sugar alcohols, for example, having a molecular weight more than 10 times higher than such small molecule excipients. For example, such polymer excipients can be used to stabilize high concentration protein formulations, such as by limiting viscosity and / or inhibiting precipitation. The present disclosure includes multiple embodiments, including but not limited to the following embodiments.
[0007] Embodiment 1 is a random polymer library comprising a mixture of polymers, wherein the library comprises polymers comprising at least three monomers selected from the group consisting of: (a) methyl methacrylate (MMA), (b) oligo(ethylene glycol) methyl ether methacrylate (OEGMA), (c) isobutyl methacrylate (IBMA) or butyl methacrylate (BMA), and (d) a compound of formula I,
[0008] Formula I:
[0009]
[0010] wherein R1 is O or NH, R2 is methyl, ethyl, propyl or butyl, and R3 is NH2 or N(CH3)2 or a guanidinium group, wherein the library includes polymers ranging from 3 kDa to 20 kDa.
[0011] Embodiment 2 is a random polymer library according to embodiment 1, wherein the library includes polymers comprising a monomer of formula I, wherein the monomer is dimethylaminomethacrylate (DMAEMA), 2-aminoethylmethacrylate, arginine methacrylate, arginine methacrylamide, N-(3-aminopropyl)methacrylamide, N-(3-methacrylamidopropyl)guanidinium chloride (ArgMAm) or N-3-(dimethylamino)propylmethacrylamide.
[0012] Embodiment 3 is a random polymer library according to embodiment 1 or 2, wherein at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the polymers in the library contain at least three monomers, or wherein the random polymer library consists essentially of polymers containing at least three monomers.
[0013] Embodiment 4 is a random polymer library according to embodiment 1 or 2, wherein at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the polymers in the library contain at least four monomers, or wherein the random polymer library consists essentially of polymers containing at least four monomers.
[0014] Embodiment 5 is a random polymer library comprising a mixture of polymers, each polymer comprising a mixture of at least three of the following monomers: methyl methacrylate (MMA), oligo(ethylene glycol) methyl ether methacrylate (OEGMA), isobutyl methacrylate (IBMA) and dimethylamino methacrylate (DMAEMA), wherein the library comprises polymers ranging from 3 kDa to 20 kDa.
[0015] Embodiment 6 is a random polymer library comprising a mixture of polymers, each polymer comprising a mixture of at least three of the following monomers: methyl methacrylate (MMA), oligo(ethylene glycol) methyl ether methacrylate (OEGMA), isobutyl methacrylate (IBMA) and N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm), wherein the library comprises polymers ranging from 3 kDa to 20 kDa.
[0016] Embodiment 7 is a random polymer library according to any one of embodiments 1 to 6, wherein the library comprises polymers ranging from 3 kDa to 15 kDa, 5 kDa to 20 kDa, 5 kDa to 15 kDa, 5 kDa to 10 kDa, 10 kDa to 20 kDa, 7 kDa to 10 kDa, or 10 kDa to 15 kDa.
[0017] Embodiment 8 is the random polymer library of any one of embodiments 1 to 7, wherein the library comprises OEGMA having a molecular weight of 300 g / mol to 1500 g / mol.
[0018] Embodiment 9 is the random polymer library according to embodiment 8, wherein the OEGMA has a molecular weight of 300 g / mol, 500 g / mol, 750 g / mol, 950 g / mol, 1000 g / mol, 1200 g / mol or 1500 g / mol.
[0019] Embodiment 10 is the random polymer library according to embodiment 8, wherein the OEGMA has a molecular weight of 500 g / mol (ie, OEGMA 500).
[0020] Embodiment 11 is a random polymer library according to any one of embodiments 1 to 4 or 7 to 10, wherein the library comprises polymers comprising three monomers.
[0021] Embodiment 12 is a random polymer library according to embodiment 11, wherein at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the polymers in the library contain three monomers, or wherein the random polymer library consists essentially of polymers containing three monomers.
[0022] Embodiment 13 is the random polymer library according to embodiment 11 or 12, wherein the three monomers are MMA, OEGMA, and any one of IBMA and BMA.
[0023] Embodiment 14 is the random polymer library according to embodiment 13, wherein the three monomers are MMA, OEGMA and IBMA.
[0024] Embodiment 15 is a random polymer library according to embodiment 13, wherein the MMA, OEGMA and IBMA or BMA are present in the following ratios: (a) 5:3:2, or (b) 3:5:2, or (c) 5:4:1.
[0025] Embodiment 16 is a random polymer library according to any one of embodiments 1 to 10, wherein the library comprises polymers comprising four monomers.
[0026] Embodiment 17 is a random polymer library according to embodiment 16, wherein at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the polymers in the library contain three monomers, or wherein the random polymer library consists essentially of polymers containing three monomers.
[0027] Embodiment 18 is the random polymer library according to embodiment 16 or 17, wherein the four monomers are MMA, OEGMA, IBMA and DMAEMA.
[0028] Embodiment 19 is the random polymer library of embodiment 18, wherein the polymer library comprises polymers comprising 20% to 50% MMA, 20% to 50% OEGMA, 5% to 25% IBMA, and 5% to 25% DMAEMA, based on the total weight of the polymer.
[0029] Embodiment 20 is a random polymer library according to embodiment 18, wherein the polymer library includes polymers comprising MMA, OEGMA, IBMA and DMAEMA in the following molar ratios: (a) 5:2.5:2:0.5, (b) 2:5:2:1, (c) 5:2.5:1:1.5, (d) 4:4:1:1; (e) 3:4:1:2; (f) 2:4:1:3; and / or (g) 2:3:1:4.
[0030] Embodiment 21 is a random polymer library according to embodiment 18, wherein the MMA, OEGMA, IBMA and DMAEMA are in the following molar ratios: 5:2.5:2:0.5, wherein the OEGMA has a molecular weight of 500 g / mol (i.e., OEGMA 500), and wherein the library includes polymers having a molecular weight of 3 kDa to 15 kDa.
[0031] Embodiment 22 is a random polymer library according to embodiment 16 or 17, wherein the four monomers are MMA, OEGMA, IBMA and ArgMAm.
[0032] Embodiment 23 is the random polymer library of embodiment 22, wherein the polymer library comprises polymers comprising 20% to 50% MMA, 20% to 50% OEGMA, 5% to 25% IBMA, and 5% to 25% ArgMAm, based on the total weight of the polymer.
[0033] Embodiment 24 is a random polymer library according to embodiment 22, wherein the polymer library comprises polymers comprising MMA, OEGMA, IBMA and ArgMAm in the following molar ratios: (a) 5:2.5:2:0.5, (b) 2:5:2:1, (c) 5:2:1:2, (d) 4:4:1:1; (e) 3:4:1:2; (f) 2:4:1:3; and / or (g) 2:3:1:4.
[0034] Embodiment 25 is a random polymer library according to embodiment 22, wherein the MMA, OEGMA, IBMA and ArgMAm are in the following molar ratios: 5:2:1:2 or 4:4:1:1, wherein the OEGMA has a molecular weight of 500 g / mol (i.e., OEGMA500), and wherein the library includes polymers with a molecular weight of 3 kDa to 15 kDa.
[0035] Embodiment 26 is a random polymer library comprising a mixture of polymers, wherein the library comprises polymers comprising at least two of the following monomers: oligo(ethylene glycol) methyl ether methacrylate (OEGMA) and either isobutyl methacrylate (IBMA) or butyl methacrylate (BMA), and / or at least two of the following monomers: oligo(ethylene glycol) methyl ether methacrylate (OEGMA) and N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm), optionally wherein the OEGMA has a molecular weight of 500 g / mol (i.e., OEGMA 500), and optionally wherein the library comprises polymers having a molecular weight of 3 kDa to 15 kDa.
[0036] Embodiment 27 is a random polymer comprising a mixture of at least three selected from the following monomers: (a) methyl methacrylate (MMA), (b) oligo(ethylene glycol) methyl ether methacrylate (OEGMA), (c) isobutyl methacrylate (IBMA) or (d) butyl methacrylate (BMA) and a compound of formula I,
[0037] Formula I:
[0038]
[0039] wherein R1 is O or NH, R2 is methyl, ethyl, propyl or butyl, and R3 is NH2 or N(CH3)2 or a guanidinium group, wherein the polymer is 3 kDa to 20 kDa.
[0040] Embodiment 28 is a random polymer according to embodiment 27, wherein the polymer comprises a monomer of formula I,
[0041] Formula I:
[0042]
[0043] The monomer is dimethylamino methacrylate (DMAEMA), 2-aminoethyl methacrylate, arginine methacrylate, arginine methacrylamide, N-(3-aminopropyl) methacrylamide, N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm) or N-3-(dimethylamino)propyl methacrylamide.
[0044] Embodiment 29 is a random polymer comprising a mixture of at least three of the following monomers: methyl methacrylate (MMA), oligo(ethylene glycol) methyl ether methacrylate (OEGMA), isobutyl methacrylate (IBMA), and dimethylamino methacrylate (DMAEMA), wherein the polymer is 3 kDa to 20 kDa.
[0045] Embodiment 30 is a random polymer comprising a mixture of at least three of the following monomers: methyl methacrylate (MMA), oligo(ethylene glycol) methyl ether methacrylate (OEGMA), isobutyl methacrylate (IBMA) and N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm), wherein the polymer is 3 kDa to 20 kDa.
[0046] Embodiment 31 is a random polymer according to any one of embodiments 27 to 30, wherein the polymer is 3 kDa to 15 kDa, 5 kDa to 20 kDa, 5 kDa to 15 kDa, 5 kDa to 10 kDa, 10 kDa to 20 kDa, 7 kDa to 10 kDa, or 10 kDa to 15 kDa.
[0047] Embodiment 32 is the random polymer of any one of embodiments 27 to 31, wherein the polymer comprises OEGMA having a molecular weight of 300 to 1500 g / mol.
[0048] Embodiment 33 is a random polymer according to embodiment 32, wherein the OEGMA has a molecular weight of 300 g / mol, 500 g / mol, 750 g / mol, 950 g / mol, 1000 g / mol, 1200 g / mol, or 1500 g / mol.
[0049] Embodiment 34 is a random polymer according to embodiment 33, wherein the OEGMA has a molecular weight of 500 g / mol.
[0050] Embodiment 35 is the random polymer of any one of embodiments 27-28 or 31-34, wherein the polymer comprises three monomers.
[0051] Embodiment 36 is the random polymer of embodiment 35, wherein the three monomers are MMA, OEGMA, and either IBMA or BMA.
[0052] Embodiment 37 is a random polymer according to embodiment 36, wherein the three monomers are MMA, OEGMA and IBMA.
[0053] Embodiment 38 is a random polymer according to embodiment 37, wherein the MMA, OEGMA and IBMA or BMA are present in the following ratios: (a) 5:3:2, or (b) 3:5:2, or (c) 5:4:1.
[0054] Embodiment 39 is the random polymer of any one of embodiments 27 to 34, wherein the polymer comprises four monomers.
[0055] Embodiment 40 is a random polymer according to embodiment 39, wherein the four monomers are MMA, OEGMA, IBMA and DMAEMA.
[0056] Embodiment 41 is a random polymer according to embodiment 40, wherein the polymer comprises 20% to 50% MMA, 20% to 50% OEGMA, 5% to 25% IBMA, and 5% to 25% DMAEMA, based on the total weight of the polymer.
[0057] Embodiment 42 is a random polymer according to embodiment 40, wherein the polymer comprises MMA, OEGMA, IBMA and DMAEMA in the following molar ratios: (a) 5:2.5:2:0.5, (b) 2:5:2:1, (c) 5:2.5:1:1.5, (d) 4:4:1:1; (e) 3:4:1:2; (f) 2:4:1:3; or (g) 2:3:1:4.
[0058] Embodiment 43 is a random polymer according to embodiment 40, wherein the MMA, OEGMA, IBMA and DMAEMA are in the following molar ratios: 5:2.5:2:0.5, wherein the OEGMA is OEGMA 500, wherein the polymer has a molecular weight of 3 kDa to 15 kDa.
[0059] Embodiment 44 is a random polymer according to embodiment 39, wherein the four monomers are MMA, OEGMA, IBMA, and ArgMAm.
[0060] Embodiment 45 is the random polymer of embodiment 44, wherein the polymer comprises 20% to 50% MMA, 20% to 50% OEGMA, 5% to 25% IBMA, and 5% to 25% ArgMAm, based on the total weight of the polymer.
[0061] Embodiment 46 is a random polymer according to embodiment 44, wherein the polymer comprises MMA, OEGMA, IBMA and ArgMAm in the following molar ratios: (a) 5:2.5:2:0.5, (b) 2:5:2:1, (c) 5:2.5:1:1.5, (d) 4:4:1:1; (e) 3:4:1:2; (f) 2:4:1:3; or (g) 2:3:1:4.
[0062] Embodiment 47 is a random polymer according to embodiment 44, wherein the MMA, OEGMA, IBMA and ArgMAm are in the following molar ratios: 5:2:1:2 or 4:4:1:1, wherein the OEGMA is OEGMA 500, wherein the polymer has a molecular weight of 3 kDa to 15 kDa.
[0063] Embodiment 48 is a random polymer comprising: a mixture of at least two of the following monomers: oligo(ethylene glycol) methyl ether methacrylate (OEGMA) and either isobutyl methacrylate (IBMA) or butyl methacrylate (BMA), and / or at least two monomers selected from the following: oligo(ethylene glycol) methyl ether methacrylate (OEGMA) and N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm), optionally wherein the OEGMA has a molecular weight of 500 g / mol (i.e., OEGMA 500), and optionally wherein the polymer has a molecular weight of 3 kDa to 15 kDa.
[0064] Embodiment 49 is the random polymer of any one of embodiments 27 to 48, wherein the polymer has a molecular weight of 7 kDa to 10 kDa.
[0065] Embodiment 50 is a composition comprising the random polymer of any one of embodiments 27 to 49, and at least one protein.
[0066] Embodiment 51 is a composition according to embodiment 50, wherein the concentration of the polymer is between 0.01% w / v and 1% w / v, such as 0.01% to 0.1% w / v.
[0067] Embodiment 52 is a composition according to embodiment 50 or 51, wherein the protein is an antibody.
[0068] Embodiment 53 is a composition according to embodiment 52, wherein the antibody is an IgG antibody, such as a full length IgG, a bispecific IgG, or wherein the antibody is an antigen binding fragment, such as Fab, Fab', (Fab')2, Fv or scFv.
[0069] Embodiment 54 is the composition of any one of embodiments 50 to 53, wherein the composition further comprises at least one buffer, such as histidine, phosphate or citrate.
[0070] Embodiment 55 is a composition according to any one of embodiments 50 to 54, wherein the composition further comprises at least one surfactant, such as a polysorbate, for example polysorbate 20 or polysorbate 80.
[0071] Embodiment 56 is a composition according to any one of embodiments 50 to 55, wherein the concentration of the antibody is between 10 mg / mL and 150 mg / mL, such as 10 mg / mL to 100 mg / mL, 20 mg / mL to 100 mg / mL, 20 mg / mL to 80 mg / mL, 10 mg / mL to 50 mg / mL, 10 mg / mL to 25 mg / mL, 25 mg / mL to 50 mg / mL, 50 mg / mL to 80 mg / mL, 50 mg / mL to 100 mg / mL or 70 mg / mL to 100 mg / mL.
[0072] Embodiment 57 is a method of reducing the viscosity of a protein-containing composition and / or inhibiting the precipitation of a protein-containing composition, comprising adding a random polymer according to any one of embodiments 27 to 49 to the composition, optionally wherein the composition comprises a protein and / or an excipient according to any one of embodiments 50 to 56.
[0073] Embodiment 58 is a method of preparing a random polymer library according to any one of embodiments 1 to 26 or a random polymer according to any one of embodiments 27 to 49, wherein the method comprises reversible addition / fragmentation chain transfer (RAFT), free radical polymerization (FRP) or atom transfer radical polymerization (ATRP).
[0074] Embodiment 59 is a method of preparing a random polymer library according to any one of embodiments 1 to 26 or a random polymer according to any one of embodiments 27 to 49, the method comprising: exposing the monomers to LED light and / or heat in the presence of a zinc tetraphenylporphyrin catalyst (ZnTPP) and a chain transfer agent.
[0075] Embodiment 60 is the method according to embodiment 59, wherein the chain transfer agent is 2-cyano-2-propyl benzodithioate, 2-cyano-2-propyldodecyl trithiocarbonate, 4-((((2-carboxyethyl)thio)carbonothioyl)thio)-4-cyanopentanoic acid, 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid, or 4-cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanoic acid (CDTPA).
[0076] Embodiment 61 is the method of embodiment 59 or 60, wherein the monomers are exposed to LED light in the presence of the ZnTPP and chain transfer agent for 3 to 18 hours.
[0077] Embodiment 62 is the method of any one of embodiments 59 to 61, wherein the polymerization is terminated by removing the LED lamp.
[0078] Embodiment 63 is the method of any one of embodiments 58 to 62, further comprising performing at least one filtration, buffer exchange, or dialysis step to separate the polymers.
[0079] Embodiment is a kit comprising a random polymer library according to any one of embodiments 1 to 26 for testing the effect of the polymers included in the library on the precipitation, viscosity and / or turbidity of a solution containing a protein, the kit optionally further comprising instructions for use.
[0080] Embodiment 65 is a kit according to embodiment 64, wherein the library comprises at least 10, at least 20, at least 50, or at least 80 different individual random polymers.
[0081] Embodiment 66 is a method of identifying a random polymer excipient for a protein solution, comprising exposing the protein solution to a random polymer library according to any one of embodiments 1 to 26 or a kit according to embodiment 64 or 65 and measuring one or more of the viscosity, turbidity, or precipitation of the solution.
[0082] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the claims.
[0083] References cited herein are incorporated herein by reference. BRIEF DESCRIPTION OF THE DRAWINGS
[0084] Figure 1 An exemplary method for evaluating the effect of each polymer in a polymer library on the precipitation of a monoclonal antibody (mAb, such as mAb G) is shown.
[0085] FIG. 2A to FIG. 2B mAb G (80 mg / mL) was shown in the presence of 100 mM NaCl ( Figure 2A ) or with 150 mM NaCl ( Figure 2B Turbidity measurements (absorbance at 600 nm) after overnight incubation of 15 mM phosphate buffer pH 7.4 with selected polymer excipients at 1.6 μM, 6.6 μM and 33 μM polymer (approximately 0.0014%, 0.006%, 0.03% polymer).
[0086] Figure 3 Shown are the precipitation kinetics of mAb G (80 mg / mL) in 15 mM phosphate buffer pH 7.4 + 150 mM NaCl and polymer excipients. Turbidity was measured using absorbance at 600 nM.
[0087] Figure 4 Shown are the precipitation kinetics of mAb G (80 mg / mL) in 15 mM phosphate buffer pH 7.4 + 150 mM NaCl and polysorbate 20 (PS20). Turbidity was measured using absorbance at 600 nM.
[0088] FIG. 5A to FIG. 5BShown is the change in viscosity of mAb G solutions (194 mg / mL in 30 mM histidine chloride (HisCl) pH 5.5) with excipients Poly ID ("Poly 1"), polysorbate 20 (PS20), and a combination of Poly ID and PS20 at different excipient concentrations. Figure 5A A graph showing the change in viscosity with increasing concentration of Poly 1D or PS20 is shown. Figure 5B Bar graphs showing the change in viscosity at specific concentrations of Poly ID, PS20, or a combination of both.
[0089] Figure 6 The dependence of the viscosity of mAb G (194 mg / mL in HisCl pH 5.5) on shear rate is shown, indicating a surface active excipient.
[0090] FIG. 7A to FIG. 7B Sample processing for turbidity / sedimentation assays is shown. Fig. 7A Shown are mAb G (80 mg / mL) after precipitation in 15 mM phosphate buffer pH 7.4 + 150 mM NaCl (A) from high throughput screening of mAb G control (left, solid box), with added Poly 1E (middle, dashed box) and with added PS20 (right, dashed box). Figure 7B Shown are mAb G with PS20 (left) or Poly 1 E (right) after centrifugation.
[0091] Figure 8 Microscale thermophoresis (MST) measurements are shown, indicating that in HisCl pH 5.5, Poly 1F (15.5 μM) and mAb AD (2 x 10 -7 Up to 1x 10 -4 M) between the weak binding.
[0092] Fig. 9 Shown are the average viscosity changes of the eight mAbs when incubated with a pool of polymers containing increasing percentage amounts of DMAEMA.
[0093] Fig.10 Shown are the average viscosity changes of the eight mAbs when incubated with a pool of polymers containing increasing percentage amounts of IBMA in the polymer.
[0094] Fig.11 Shown are the average viscosity changes of the eight mAbs when incubated with polymer pools containing increasing percentage amounts of OEGMA.
[0095] Fig.12Shown are the average viscosity changes of 8 mAbs when incubated with Poly1, Poly11, Poly3, Poly5, Poly7, or Poly9, each with a molecular weight of 10 kDa.
[0096] FIG. 13A to FIG. 13B HPLC traces of (13A) crude and (13B) purified Poly 1H are shown, demonstrating elimination of DMSO (retention time approximately 7 minutes).
[0097] FIG. 14A to FIG. 14B Exemplary absorbance measurements of exemplary polymer precipitates at 320 nm (14A) and 600 nm (14B) are shown.
[0098] Fig.15 Shown are absorbance measurements at 600 nm of exemplary polymer turbidity as a function of time.
[0099] FIG. 16A to FIG. 16D Shown are absorbance measurements at 600 nm of exemplary polymer turbidity as a function of time.
[0100] Fig.17 The maximum absorbance (A) of the exemplary polymers is shown. max ). Dark grey indicates little or no improvement, light grey indicates moderate improvement, and white indicates greatly improved precipitation kinetics compared to the control. Bold text indicates polymers with no dark grey classification and at least two white classifications.
[0101] FIG. 18A to FIG. 18B Shown is the precipitation of mAB-G with and without exemplary polymers at 37°C in 15 mM phosphate buffer pH 7.4 with 150 mM NaCl.
[0102] FIG. 19A to FIG. 19H Precipitation assessment using a low-throughput physiologically relevant model is shown. The solubility of mAb-G in phosphate buffer pH 7.4 + 150 mM NaCl at 37°C in Eppondorf tubes was assessed by (19A) soluble concentration of mAb-G and (19B) weight of mAb-G precipitate after drying after centrifugation of solids (n=3); **p<0.005 between Poly1 and no additives. mAB-G precipitation (representative 3; 19C-E) and pharmacokinetics (PK; n=3; 19F) were assessed in the SCISSOR system. Figure 19G Shown is Poly 1 (n=3) released from a SCISSOR cartridge. Fig.19H DLS of Poly1 micelles in 20 mM HesCl pH 5.5 is shown.
[0103] FIG. 20A to FIG. 20B Shown are SCISSOR images (20A) and transmission data (20B) from a 0.2 mL injection of 50 mg / mL mAb-G.
[0104] FIG. 21A to FIG. 21D Shown are biophysical characterizations of the mAb-G-Poly1 interaction using microthermophoresis (MST; 21A), isothermal titration calorimetry (ITC; representation 3; 21B), and intrinsic fluorescence quenching (n=3; 21C) and corresponding Stern-Volmer plots (21D).
[0105] Fig. 22 Shown are the cytotoxicity of several concentrations of Poly 1 in Jurkat cells using trypan blue to assess cell membrane integrity (n=4).
[0106] Fig.23 Shown is the ITC curve of 1 mM mAb-G with 100 μM Poly1.
[0107] Fig.24 The ArgMAm in DMSO-d6 is shown. 1 H-NMR.
[0108] Fig.25 Shown is the expression of Poly1 in DMSO-d6 1 H-NMR.
[0109] Fig.26 The GPC trace of Poly 1 is shown.
[0110] Fig. 27 Shown is dynamic light scattering (DLS) of Poly 1 micelles in 30 mM HisCl pH 5.5.
[0111] FIG. 28A to FIG. 28D The hanging drop tensiometer ST measurements are shown for Poly 1 concentrations of 0.1% (28A), 0.02% (28B), and 0.002% (28C). Fig.28D Surface tension measurements (in mN / m) are shown for Poly 1 concentrations of 0.1% (28A), 0.02% (28B), and 0.002% (28C). DETAILED DESCRIPTION
[0112] I. Definitions
[0113] The present invention may be understood more readily by reference to the following detailed description of specific embodiments and the Examples included herein.
[0114] Unless otherwise defined, scientific and technical terms related to the present invention shall have the meanings commonly understood by those of ordinary skill in the art. In addition, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.
[0115] In this application, the use of "or" means "and / or" unless otherwise stated. In the context of multiple dependent claims, the use of "or" only refers back to more than one preceding independent or dependent claim in an alternative manner. In addition, unless specifically stated otherwise, terms such as "element" or "component" encompass elements and components comprising one unit as well as elements and components comprising more than one subunit.
[0116] As described herein, unless otherwise indicated, any concentration range, percentage range, ratio range or integer range should be understood to include any integer value within the range and fractional values thereof (e.g., one tenth and one hundredth of an integer) where appropriate.
[0117] Units, prefixes and symbols are expressed in their Système International de Unites (SI) accepted form. Numerical ranges are inclusive of the digits defining the range. Measured values are understood to be approximate, taking into account significant digits and errors associated with measurements.
[0118] As used herein, percentages ("%") are by weight to volume ("w / v") unless otherwise indicated.
[0119] The present disclosure relates to various protein-containing formulations. Such "formulations" may also be referred to herein interchangeably as "compositions" or "preparations" or "solutions".
[0120] "Polypeptide" or "protein" means a sequence of amino acids of sufficient chain length to produce a tertiary structure. Thus, proteins herein are distinguished from "peptides", which are short molecules based on amino acids, generally without any tertiary structure. Typically, proteins for use herein will have a minimum molecular weight of at least about 5 kD-20 kD, alternatively, at least about 15 kD-20 kD, preferably, at least about 20 kD. For example, polypeptides or proteins herein include antibodies.
[0121] As used herein, the term "antibody" includes polyclonal antibodies, monoclonal antibodies (including full-length antibodies with immunoglobulin Fc regions), antibody compositions with multi-epitope specificity, bispecific antibodies and multispecific antibodies (including diabodies, one-armed antibodies and single-chain molecules), and antigen-binding fragments (e.g., Fab, F(ab')2, scFv and Fv). The antibodies herein include a set of complementary determining regions (CDRs) located in the heavy (H) and light (L) chain variable domains that jointly recognize a specific antigen. The antibodies herein include at least a portion of the heavy chain and light chain variable domain amino acid sequences sufficient to include a CDR set for antigen recognition. In some embodiments, the antibody includes full-length heavy and light chain variable domains. In some embodiments, the antibody further includes a heavy chain and / or light chain constant region, which may or may not be full-length.
[0122] The term "immunoglobulin" (Ig) is used interchangeably herein with "antibody."
[0123] As used herein, the term "stabilizing agent" or "stabilizer" is a chemical or compound added to a formulation to keep it in a stable or unchanged state. In some cases, stabilizers may be added to help prevent precipitation, aggregation, oxidation, color change, etc. Depending on the circumstances, stabilizers may include small molecules such as amino acids, sugars and sugar alcohols, as well as certain proteins (e.g., albumin), surfactants, and polymers.
[0124] "Surfactants" are molecules with well-defined polar and non-polar regions that allow them to aggregate in solution to form micelles. Depending on the nature of the polar regions, surfactants can be nonionic, anionic, cationic, and zwitterionic.
[0125] As used herein, "polymer" refers to a molecule comprising linear or branched repeating monomer elements.
[0126] "Random polymer" is such a polymer, wherein the individual different monomers constituting the polymer chain are not in a specific, predetermined order along the length of the chain. "Random polymer library" or "mixture of random polymers" refers to, for example, a mixture of random polymers of different lengths, different molecular weights and / or different individual monomer mol ratios interchangeably. In certain embodiments, the random polymer library may include random polymers with the same monomer group and the same monomer ratio but with different chain lengths or molecular weights. In other embodiments, the library may include random polymers with the same chain length or molecular weight and with the same monomer group but with different individual monomer mol ratios. In certain embodiments, the library may include random polymers with different monomer groups, but for example, the mol ratios of different monomers are the same and / or the chain lengths are the same.
[0127] As used herein, "chain transfer agent" refers to a molecule added to a polymerization reaction that may function to control or slow down the growth of the polymer chain during the polymerization process.
[0128] "Buffer" may be included in some protein formulations and is a substance that helps control the pH of the formulation. Examples of buffers used in therapeutic formulations include, for example, phosphate, citrate, and histidine. Laboratory formulations may typically include buffers such as Tris, HEPES, etc.
[0129] The term "pharmaceutical formulation" or "therapeutic formulation" or "therapeutic preparation" refers to a preparation or composition comprising at least one active ingredient (e.g., a protein) and at least one additional component or excipient substance, and is in a form that permits the biological activity of the active ingredient to be effective in an animal subject (such as a mammal), and is "suitable for therapeutic use" or "suitable for pharmaceutical use," meaning that the formulation as a whole is not unacceptably toxic to the subject and does not contain components that are unacceptably toxic to the subject to which the formulation is to be administered or at concentrations that would make them unacceptably toxic to the subject.
[0130] A "stable" formulation is one in which the protein substantially maintains its physical stability and / or chemical stability during storage and administration. Stability can be measured over a selected time period at a selected temperature. Various analytical techniques for measuring protein stability are available in the art and are reviewed in, for example, Peptide and Protein Drug Delivery, 247-301, Vincent Lee, ed., Marcel Dekker, Inc., New York, NY, Pubs. (1991) and Jones, A. Adv. Drug Delivery Rev. 10: 29-90 (1993).
[0131] Increasing the "stability" of a protein-containing formulation may involve reducing (compared to an untreated protein-containing formulation) or preventing the formation of precipitates, protein aggregates or degradation products, reducing oxidation and color changes, and the like.
[0132] As used herein, the term "aggregate" or "aggregation" refers to gathering together or gathering into a mass or whole, such as in the aggregation of protein molecules. Aggregates can be self-aggregated or aggregated due to other factors, such as the presence of aggregating agents, precipitants, stirring, or other ways and methods of protein causing aggregation. Aggregation can be visually observed, such as when a previously clarified protein preparation in a solution becomes turbid or contains precipitation, or by methods such as size exclusion chromatography (SEC), which separates proteins in a preparation by size. Aggregates can include dimers, trimers, and polymers of protein substances. As used herein, "high molecular weight substances" (HMWS) refer to aggregates of proteins that can be observed, for example, by size exclusion chromatography, and they at least represent dimers of desired protein molecules, i.e., have at least twice the molecular weight of the desired protein substance in the preparation. In the case of protein substances, such as antibodies, their normal or desired form is already a polymer, such as for dimers or tetramers, HMWS will at least represent dimers of the normal, desired polymer form of the protein.
[0133] "Isolated" when used to describe the various polypeptides and antibodies disclosed herein means a polypeptide or antibody that has been identified, separated and / or recovered from components of its production environment. Alternatively, an isolated polypeptide is free from association with all other components from its production environment. Contaminant components of its production environment, such as contaminants produced by recombinant transfected cells, are substances that would normally interfere with the diagnostic or therapeutic use of the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes.
[0134] In some embodiments herein, the pharmaceutical formulation "does not include" one or more types of excipients or ingredients, such as surfactants or amino acid excipients, etc. The expression "does not include" in this context means that the excluded ingredients are not present at more than trace levels, for example, due to contamination or impurities found in other intentionally added ingredients.
[0135] The term "consisting essentially of," when referring to a mixture of ingredients of a formulation herein, means that, although ingredients not expressly listed may be present, such ingredients are present only in trace amounts or are otherwise present in sufficiently low amounts that certain essential properties of the formulation, including protein concentration (such as the degree of protein precipitation), turbidity, viscosity, are not altered.
[0136] II. Exemplary Random Polymer Libraries and Selected Polymers
[0137] Embodiments herein include random polymer libraries composed of a plurality of random polymers. Embodiments herein also include specific random polymers, such as those having specific relative concentrations of a specific set of monomers and a specific average chain length or molecular weight.
[0138] In some cases, the random polymer of the random polymer library comprises a mixture of at least three different monomers, such as acrylate and / or acrylamide monomers. In some cases, in the library, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95% of the polymers have at least three monomers, for example, wherein the remaining polymers in the library have one to two monomers. In some cases, in the library, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95% of the polymers have at least four monomers, for example, wherein the remaining polymers in the library have one to three monomers. In some cases, in the library, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95% of the polymers have three monomers, for example, wherein the remaining polymers in the library have one or two or four or more than four monomers or a mixture of these possible monomers. In some cases, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of the polymers in a library have four monomers, for example, with the remaining polymers in the library having one, two, or three or more than four monomers or a mixture of these possible monomers.
[0139] In some cases, the polymer in the library is essentially composed of at least two, at least three or at least four monomers. In some embodiments, the random polymer library is essentially composed of polymers with three or four monomers. In some cases, the library is essentially composed of polymers with three monomers. In other cases, the library is essentially composed of polymers with four monomers. In such cases, the polymers in the library are each intended to be composed of a specific number of monomers, but due to the complexity of chemical synthesis, the library may contain a small amount of polymers with different numbers of monomers.
[0140] In some cases, the random polymer library includes polymers having a mixture of at least three of the following monomers: methyl methacrylate (MMA), oligo(ethylene glycol) methyl ether methacrylate (OEGMA), isobutyl methacrylate (IBMA), butyl methacrylate (BMA), dimethylaminomethacrylate (DMAEMA), (4-hydroxyphenyl)methacrylamide, 2-hydroxyethyl methacrylate, [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide, 2-aminoethyl methacrylate, arginine methacrylate, arginine methacrylamide, N-(3-aminopropyl)methacrylamide, N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm), or N-3-(dimethylamino)propylmethacrylamide. In some cases, the random polymer library includes polymers having a mixture of at least three monomers selected from oligo(ethylene glycol)methyl ether methacrylate (OEGMA) and any of the following additional monomers: methyl methacrylate (MMA), isobutyl methacrylate (IBMA), butyl methacrylate (BMA), dimethylaminomethacrylate (DMAEMA), (4-hydroxyphenyl)methacrylamide, 2-hydroxyethyl methacrylate, [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide, 2-aminoethyl methacrylate, arginine methacrylate, arginine methacrylamide, N-(3-aminopropyl)methacrylamide, N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm), or N-3-(dimethylamino)propylmethacrylamide. In some cases, the library includes polymers having only one of isobutyl methacrylate (IBMA) and butyl methacrylate (BMA), but not both. In some cases, only one of dimethylaminomethacrylate (DMAEMA), (4-hydroxyphenyl)methacrylamide, 2-hydroxyethylmethacrylate, [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide, 2-aminoethylmethacrylate, arginine methacrylate, arginine methacrylamide, N-(3-aminopropyl)methacrylamide, N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm), and N-3-(dimethylamino)propylmethacrylamide is selected.
[0141] In some embodiments herein, the random polymer library includes polymers comprising three or more monomers selected from: (a) methyl methacrylate (MMA), (b) oligo(ethylene glycol) methyl ether methacrylate (OEGMA), (c) any one of isobutyl methacrylate (IBMA) or butyl methacrylate (BMA). In some embodiments herein, the random polymer library includes three or more monomers selected from: (a) methyl methacrylate (MMA), (b) oligo(ethylene glycol) methyl ether methacrylate (OEGMA), (c) any one of isobutyl methacrylate (IBMA) or butyl methacrylate (BMA) and (d) at least one compound of Formula I,
[0142] Formula I:
[0143]
[0144] Wherein R1 is O or NH, R2 is methyl, ethyl, propyl or butyl, and R3 is NH2 or N(CH3)2 or OH, or wherein R1 is O or NH and R2 and R3 together comprise hydroxyphenyl, such as 4-hydroxyphenyl, or wherein R1 is O or NH and R2 is N,N-dimethylethylamine group, and R3 is sulfopropyl group. Such library includes monomers such as from (a), (b) and (c); or alternatively (a), (b) and (d); or (b), (c) and (d); or (a), (c) and (d); or each of (a)-(d), and thus includes a total of at least three different monomers. In some cases, the library can include a mixture of polymers, each polymer having different monomer groups from these options. In other cases, the library can contain polymers, each polymer having the same monomer group, but different relative concentrations and / or different lengths or molecular weights, depending on the reaction conditions.
[0145] In some embodiments, the present disclosure includes a random polymer library including a polymer comprising a mixture of at least three monomers selected from: (a) methyl methacrylate (MMA), (b) oligo(ethylene glycol) methyl ether methacrylate (OEGMA), (c) isobutyl methacrylate (IBMA) or butyl methacrylate (BMA), and (d) a compound of formula I,
[0146] Formula I:
[0147]
[0148] wherein R1 is O or NH, R2 is methyl, ethyl, propyl or butyl, and R3 is NH2 or N(CH3)2 or a guanidinium group (e.g., H2N-C(=NH2 +)-NH2), wherein the library includes polymers of 3kDa to 20kDa. As described above, such libraries include, for example, monomers from each of (a), (b) and (c); or alternatively (a), (b) and (d); or (b), (c) and (d); or (a), (c) and (d); or (a)-(d), etc., and thus include a total of at least three different monomers. And, as described above, in some cases, the library can include a mixture of polymers, each polymer having a different set of monomers from these options. In other cases, the library can contain polymers, each polymer having the same set of monomers, but with different relative concentrations and / or different lengths or molecular weights, depending on the reaction conditions. In some cases, the library includes polymers comprising a monomer of Formula I, wherein the monomer is dimethylaminomethacrylate (DMAEMA), 2-aminoethylmethacrylate, arginine methacrylate, arginine methacrylamide, N-(3-aminopropyl)methacrylamide, N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm), or N-3-(dimethylamino)propylmethacrylamide. In some cases, the library includes polymers comprising at least three of: methyl methacrylate (MMA), oligo(ethylene glycol)methyl ether methacrylate (OEGMA), isobutyl methacrylate (IBMA), and dimethylaminomethacrylate (DMAEMA), or four of those monomers. In some cases, the random polymer library includes at least one monomer of Formula I selected from dimethylaminomethacrylate (DMAEMA), 2-hydroxyethylmethacrylate, 2-aminoethylmethacrylate, arginine methacrylate, arginine methacrylamide, N-(3-aminopropyl)methacrylamide, N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm), or N-3-(dimethylamino)propylmethacrylamide.
[0149] In any of the above cases, the library sometimes includes polymers with three monomers. In other cases, the library includes polymers with four monomers. In still other cases, five monomers are used.
[0150] In some cases, the library includes the polymer of three kinds of monomers, wherein three kinds of monomers are MMA, OEGMA and IBMA or BMA.In some cases, these three kinds of monomers are MMA, OEGMA and IBMA.In some cases, the library includes the polymer of four kinds of monomers: MMA, OEGMA, IBMA or BMA, and one of the following: DMAEMA, arginine methacrylate, arginine methacrylamide, N-(3-aminopropyl) methacrylamide or N-(3-methacrylamidopropyl) guanidine hydrochloride (ArgMAm).In some cases, these four kinds of monomers are MMA, OEGMA, IBMA or BMA and DMAEMA or ArgMAm.In some cases, these four kinds of monomers are MMA, OEGMA, IBMA or BMA and DMAEMA.In some cases, these four kinds of monomers are MMA, OEGMA, IBMA or BMA and ArgMAm.In some cases, these four kinds of monomers are MMA, OEGMA, IBMA or BMA and ArgMAm. In some cases, the four monomers are MMA, OEGMA, IBMA and DMAEMA. In some cases, the four monomers are MMA, OEGMA, IBMA and ArgMAm. In some cases, the polymer in the library comprises a mixture of IBMA and BMA and MMA and OEGMA. In some cases, the polymer in the library comprises a mixture of IBMA and BMA. In some cases, the polymer in the library comprises more than one compound of formula I, such as DMAEMA and ArgMAm.
[0151] In other embodiments, the random polymer library includes a polymer with two monomers. In certain embodiments, the two monomers are BMA or IBMA and OEGMA. In some cases, the two monomers are IBMA and OEGMA. In some cases, the two monomers are BMA and OEGMA. In other cases, the two monomers are ArgMAm and OEGMA.
[0152] In any of the above cases, in some embodiments, the library includes polymers from 3kDa to 20kDa. In some embodiments, the library includes polymers from a library that includes polymers from 3kDa to 15kDa, 5kDa to 20kDa, 5kDa to 15kDa, 5kDa to 10kDa, 5kDa to 8kDa, 10kDa to 20kDa, 7kDa to 10kDa, 8kDa to 10kDa, 10kDa to 12kDa, 12kDa to 15kDa, or 10kDa to 15kDa. For example, a polymer library can be created that has polymers of various lengths and therefore various molecular weights.
[0153] When OEGMA is present, in some embodiments, the library comprises OEGMA with a molecular weight of 300 g / mol to 1500 g / mol. In some such embodiments, OEGMA may have a molecular weight of 300 g / mol, 500 g / mol, 750 g / mol, 950 g / mol, 1000 g / mol, 1200 g / mol, or 1500 g / mol. In some cases, it has a molecular weight of 500 g / mol (i.e., OEGMA500). In some cases, a random polymer library can also be created with the size of OEGMA as a variable to be changed, so that the library includes polymers with different OEGMA sizes, but in addition, for example, the same set of monomers, optionally with the same relative concentration and / or with the same approximate chain length.
[0154] In some embodiments, a random polymer library can be prepared, which includes polymers with a certain range of monomer molar ratios, or includes polymers with a set of specific molar ratios, but the polymers are different in, for example, length or molecular weight of OEGMA (if OEGMA exists) or in another variable parameter. In some embodiments, the polymer in the library includes 20% to 50% MMA, 20% to 50% OEGMA and 5% to 25% IBMA by total polymer weight. In some such cases, the polymer is prepared by a monomer consisting essentially of: DMAEMA, IBMA and OEGMA, for example, 20% to 50% MMA, 20% to 50% OEGMA and 5% to 25% IBMA by total weight of polymerization. In other cases, there is also at least one additional monomer, such as DMAEMA or ArgMAm. In some cases, the polymer may include 20% to 50% MMA, 20% to 50% OEGMA, 5% to 25% IBMA and 5% to 25% DMAEMA. In some embodiments, the polymers in the library comprise DMAEMA or ArgMAm, IBMA, OEGMA and MMA, and are optionally present as follows: MMA, OEGMA, IBMA and DMAEMA or ArgMAm in the following molar ratios: (a) 5:2.5:2:0.5, (b) 2:5:2:1, (c) 5:2.5:1:1.5, (d) 4:4:1:1; (e) 3:4:1:2; (f) 2:4:1:3; (g) 2:3:1:4 or (h) 5:2:1:2. In some embodiments, MMA, OEGMA, IBMA and DMAEMA are in the following molar ratio: 5:2.5:2:0.5, wherein the OEGMA has a molecular weight of 500 g / mol (i.e., OEGMA500), wherein the library includes polymers having a molecular weight of 3 kDa to 15 kDa. In some embodiments, the polymer library can be prepared from MMA, OEGMA, and IBMA in the following molar ratios: 5:4:1 or 5:3:2 or 3:5:2. And such polymer library can have a molecular weight range of 3 kDa to 15 kDa. In some cases, the OEGMA can be OEGMA 500.
[0155] Embodiments herein include random polymers made from a mixture of at least three different monomers such as acrylate and / or acrylamide monomers. In some cases, the random polymer comprises a mixture of at least three selected from the following monomers: methyl methacrylate (MMA), oligo(ethylene glycol)methyl ether methacrylate (OEGMA), isobutyl methacrylate (IBMA), butyl methacrylate (BMA), dimethylaminomethacrylate (DMAEMA), (4-hydroxyphenyl)methacrylamide, 2-hydroxyethylmethacrylate, [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide, 2-aminoethylmethacrylate, arginine methacrylate, arginine methacrylamide, N-(3-aminopropyl)methacrylamide, N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm), or N-3-(dimethylamino)propylmethacrylamide. In some cases, the polymer comprises a mixture of at least three monomers selected from oligo(ethylene glycol)methyl ether methacrylate (OEGMA) and any of the following additional monomers: methyl methacrylate (MMA), isobutyl methacrylate (IBMA), butyl methacrylate (BMA), dimethylamino methacrylate (DMAEMA), (4-hydroxyphenyl)methacrylamide, 2-hydroxyethyl methacrylate, [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide, 2-aminoethyl methacrylate, arginine methacrylate, arginine methacrylamide, N-(3-aminopropyl)methacrylamide, N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm), or N-3-(dimethylamino)propylmethacrylamide. In some cases, the polymer comprises only one of isobutyl methacrylate (IBMA) and butyl methacrylate (BMA), but not both.
[0156] In some embodiments herein, the random polymer comprises three or more monomers selected from: (a) methyl methacrylate (MMA), (b) oligo(ethylene glycol) methyl ether methacrylate (OEGMA), (c) any one of isobutyl methacrylate (IBMA) or butyl methacrylate (BMA), and (d) at least one compound of Formula I,
[0157] Formula I:
[0158]
[0159] wherein R1 is O or NH, R2 is methyl, ethyl, propyl or butyl, and R3 is NH2 or N(CH3)2 or OH, or wherein R1 is O or NH and R2 and R3 together comprise a hydroxyphenyl group, such as a 4-hydroxyphenyl group, or wherein R1 is O or NH and R2 is an N,N-dimethylethylamine group, and R3 is a sulfopropyl group. Such polymers comprise, for example, monomers from each of (a), (b) and (c); or alternatively (a), (b) and (d); or (b), (c) and (d); or (a), (c) and (d); or (a)-(d), etc., and thus include a total of at least three different monomers.
[0160] In some embodiments, the present disclosure includes a random polymer comprising a mixture of at least three of the following monomers: (a) methyl methacrylate (MMA), (b) oligo(ethylene glycol) methyl ether methacrylate (OEGMA), (c) isobutyl methacrylate (IBMA) or butyl methacrylate (BMA), and (d) a compound of formula I
[0161] Formula I:
[0162]
[0163] Wherein R1 is O or NH, R2 is methyl, ethyl, propyl or butyl, and R3 is NH2 or N(CH3)2 or a guanidinium group, wherein the library includes polymers of 3 kDa to 20 kDa. As described above, such polymers include monomers from, for example, (a), (b) and (c); or alternatively (a), (b) and (d); or (b), (c) and (d); or (a), (c) and (d); or each of (a)-(d), etc., and thus include a total of at least three different monomers. In some cases, the polymer includes a monomer of Formula I, wherein the monomer is dimethylaminomethylacrylate (DMAEMA), 2-aminoethylmethacrylate, arginine methacrylate, arginine methacrylamide, N-(3-aminopropyl)methacrylamide or N-3-(dimethylamino)propylmethacrylamide. In some cases, the polymer comprises at least three of the following: methyl methacrylate (MMA), oligo(ethylene glycol) methyl ether methacrylate (OEGMA), isobutyl methacrylate (IBMA), dimethylaminomethacrylate (DMAEMA), and N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm), or comprises four of those monomers. In some cases, the random polymer comprises at least one monomer of Formula I selected from dimethylaminomethacrylate (DMAEMA), 2-hydroxyethylmethacrylate, 2-aminoethylmethacrylate, arginine methacrylate, arginine methacrylamide, N-(3-aminopropyl)methacrylamide, N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm), or N-3-(dimethylamino)propylmethacrylamide.
[0164] In any of the above cases, the polymer sometimes has three monomers. In other cases, it has four monomers. In still other cases, five monomers are used.
[0165] In some cases, polymer comprises three monomers, wherein the three monomers are any one of MMA, OEGMA and IBMA or BMA. In some cases, the three monomers are MMA, OEGMA and IBMA. In some cases, polymer comprises the following four monomers: MMA, OEGMA, IBMA or BMA and DMAEMA or ArgMAm. In some cases, the four monomers are MMA, OEGMA, IBMA or BMA and DMAEMA. In some cases, the four monomers are MMA, OEGMA, IBMA or BMA and ArgMAm. In some cases, the four monomers are MMA, OEGMA, IBMA or BMA and DMAEMA. In some cases, the four monomers are MMA, OEGMA, IBMA and DMAEMA or ArgMAm. In some cases, the four monomers are MMA, OEGMA, IBMA and DMAEMA. In some cases, the four monomers are MMA, OEGMA, IBMA and ArgMAm. In some cases, the four monomers are MMA, OEGMA, IBMA and DMAEMA. In some cases, the four monomers are MMA, OEGMA, IBMA and ArgMAm. In some cases, polymer comprises a mixture of IBMA and BMA and MMA and OEGMA. In some cases, polymer comprises a mixture of IBMA and BMA. In some cases, the polymer comprises more than one compound of Formula I, such as both DMAEMA and ArgMAm.
[0166] In other embodiments, the random polymer comprises two monomers. In some embodiments, the two monomers are BMA or IBMA and OEGMA. In some cases, the two monomers are IBMA and OEGMA. In some cases, the two monomers are BMA and OEGMA. In other cases, the two monomers are ArgMAm and OEGMA.
[0167] In any of the above cases, in some embodiments, the polymer has an average molecular weight of 3 kDa to 20 kDa. In some embodiments, the library includes polymers from a library including an average molecular weight of 3 kDa to 15 kDa, 5 kDa to 20 kDa, 5 kDa to 15 kDa, 5 kDa to 10 kDa, 5 kDa to 8 kDa, 10 kDa to 20 kDa, 7 kDa to 10 kDa, 8 kDa to 10 kDa, 10 kDa to 12 kDa, 12 kDa to 15 kDa, or 10 kDa to 15 kDa.
[0168] When OEGMA is present, in some embodiments, the polymer comprises OEGMA having a molecular weight of 3001500 g / mol to 1500 g / mol. In some such embodiments, OEGMA may have a molecular weight of 300 g / mol, 500 g / mol, 750 g / mol, 950 g / mol, 1000 g / mol, 1200 g / mol, or 1500 g / mol. In some cases, it has a molecular weight of 500 g / mol (i.e., OEGMA500).
[0169] In some embodiments, the polymer may include 20% to 50% MMA, 20% to 50% OEGMA, 5% to 25% IBMA by total polymer weight. In some such cases, the polymer may be prepared from monomers consisting essentially of DMAEMA, IBMA and OEGMA, such as 20% to 50% MMA, 20% to 50% OEGMA, 5% to 25% IBMA by total polymer weight. In other cases, at least one additional monomer, such as DMAEMA or ArgMAm, is also present. In some cases, the polymer may include 20% to 50% MMA, 20% to 50% OEGMA, 5% to 25% IBMA and 5% to 25% DMAEMA. In some embodiments, the polymer comprises DMAEMA or ArgMAm, IBMA, OEGMA and MMA. In some cases, the monomers are present in the following relative molar ratios of MMA, OEGMA, IBMA, and DMAEMA or ArgMAm: (a) 5:2.5:2:0.5, (b) 2:5:2:1, (c) 5:2.5:1:1.5, (d) 4:4:1:1; (e) 3:4:1:2; (f) 2:4:1:3; (g) 2:3:1:4; or (h) 5:2:1:2. In some embodiments, MMA, OEGMA, IBMA, and DMAEMA are in the following molar ratio: 5:2.5:2:0.5, wherein OEGMA has a molecular weight of 500 g / mol (i.e., OEGMA 500), and wherein the polymer comprises a molecular weight of 3 kDa to 15 kDa. In some embodiments, the polymer may be prepared from MMA, OEGMA, and IBBMA in the following molar ratios: 5:4:1 or 5:3:2 or 3:5:2. And such polymer may have a molecular weight of 3 kDa to 15 kDa. In some cases, the OEGMA may be OEGMA 500.
[0170] Some specific exemplary polymers herein include, for example, Poly1, Poly3, Poly5, Poly7, Poly9 and Poly11, which include MMA, OEGMA, IBMA and / or DMAEMA in the following molar ratios: Poly 1:5:2.5:2:0.5, Poly 3:2:5:2:1, Poly 5:5:2.5:1:1.5, Poly 11:4:4:1:1; Poly 9:3:5:2:0; and (f) Poly 7:5:3:2:0. In some such cases, OEGMA has a molecular weight of 500 g / mol (i.e., OEGMA 500), and the polymer includes a molecular weight of 3 kDa to 15 kDa. In certain embodiments, a library includes one or more of the above-mentioned polymers Poly1, Poly3, Poly5, Poly7, Poly9 or Poly11, and its length range, for example, corresponds to a molecular weight of 3 kDa to 15 kDa. The corresponding polymers of different lengths / molecular weights in the library can be designated by letters A to H according to their average molecular weights of 3 kDa to 15 kDa. Thus, for example, Poly 1A comprises an average molecular weight of about 3 kDa and is prepared from MMA, OEGMA, IBMA, and DMAEMA in the following molar ratios: 5:2.5:2:0.5.
[0171] Further exemplary polymers herein include, for example, Poly 20, Poly 21, and Poly 22, including MMA, OEGMA 500, IBMA, and / or ArgMAm in the following molar ratios: Poly 20: 5:2: 1:2; Poly 21: 0:5:4: 1; and Poly 22: 4:4: 1: 1.
[0172] The disclosure herein also encompasses specific polymer libraries that can be used as test excipients for specific protein formulations. For example, the disclosure encompasses an article of manufacture comprising a microtiter plate or similar series of containers that contain aliquots of polymer library members that can be added to a specific protein formulation to test their effects on turbidity, viscosity, and other parameters of the formulation. III. Preparing Polymers and Polymer Libraries
[0173] The present disclosure also encompasses methods for preparing polymers or polymer libraries as described herein. Acrylate and acrylamide polymers can also be prepared, for example, using reversible addition / fragmentation chain transfer (RAFT), free radical polymerization (FRP) and atom transfer radical polymerization (ATRP). See, for example, S. Perrier, Macromolecules 50:7433-47 (2017); K. Matyjaszewski, Macromolecules 45 (10): 4015-39 (2012), respectively, for RAFT and ATRP methods. In some embodiments, a polymer is prepared in a method comprising exposing the selected monomer to an LED lamp in the presence of a tetraphenylporphyrin zinc catalyst (ZnTPP). In some cases, a chain transfer agent can be added to the reaction mixture, for example to control the polymerization process and the addition of different monomers. The amount of chain transfer agent and / or catalyst can also help control the average length or average molecular weight of the polymer. Examples of chain transfer agents include 2-cyano-2-propyl dithiobenzoate, 2-cyano-2-propyl dodecyl trithiocarbonate, 4-((((2-carboxyethyl)thio)thiocarbonyl)thio)-4-cyanopentanoic acid, 4-cyano-4-(phenylthiocarbonylthio)pentanoic acid, or 4-cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanoic acid (CDTPA). (See, e.g., Perrier, cited above.) For example, exemplary methods for preparing the polymers and libraries herein are described in Example 1 below. Methods for preparing random polymers and polymer libraries compatible with the polymers and libraries described herein include, for example, those described in Gromley, AJ et al., Angew. Chem. Int. ed. 2018 vol. 57(6), pp. 1557-1562 and Ng. G. et al., Macromolecules 2018 vol. 51(9) pp. 7600-7607.
[0174] IV. Protein Preparations and Their Characteristics
[0175] Embodiments herein also include protein-containing formulations comprising a polymeric excipient described herein. In some embodiments, the protein is an antibody (such as a monoclonal antibody) or an antigen-binding fragment thereof.
[0176] In some embodiments, the protein (such as an antibody) is present at a concentration of 20 mg / mL to 250 mg / mL, such as 20 mg / mL to 200 mg / mL, 50 mg / mL to 200 mg / mL, 50 mg / mL to 150 mg / mL, 20 mg / mL to 100 mg / mL, 50 mg / mL to 100 mg / mL, 80 mg / mL to 120 mg / mL, 100 mg / mL to 200 mg / mL, or 150 mg / mL to 200 mg / mL. In some embodiments, the protein formulation further comprises at least one buffer.
[0177] In some embodiments, the polymer excipient herein is present at a concentration of 0.001% to 1% w / v, such as 0.01% to 1% w / v or 0.01% to 0.1% w / v. In some embodiments, the polymer excipient is present at 1 μM to 100 μM, such as 1 μM to 50 μM, 10 μM to 100 μM or 10 μM to 50 μM.
[0178] In some embodiments, the protein formulation further comprises a surfactant, such as polysorbate 20 (PS20), polysorbate 80 (PS80), pluronics, such as poloxamer 188 or pluronic F68, or Brij, and a surfactant, such as an alkyl glycoside, such as octyl maltoside, decyl maltoside, dodecyl maltoside or octyl glucoside, a cholate surfactant such as CHAPS (3-[(3-cholamidopropyl)dimethylamino]-1-propanesulfonate), SGH (sodium glycocholate hydrate), sodium taurocholate hydrate (STH), sodium cholate hydrate (SCH), SdTH, SdCH, ScdCH or BigCHAP (N,N'-bis-(3-D-glucosamidopropyl)cholamido). In other embodiments, the protein formulation does not comprise a surfactant. If present, the surfactant is, in some embodiments, present at a concentration of, for example, 0.001% to 1% w / v, such as 0.01% to 0.1% w / v.
[0179] In some embodiments, the protein formulation includes a stabilizer, such as an amino acid, a sugar, a sugar alcohol, or an albumin. In some embodiments, there is no such stabilizer (i.e., the formulation does not include any amino acid, sugar, sugar alcohol, or albumin as a stabilizer).
[0180] In some formulations, the formulation includes a salt such as sodium chloride or potassium chloride, acetate, citrate or phosphate, or such as arginine succinate, arginine hydrochloride or histidine hydrochloride. In other cases, the formulation does not include such salts.
[0181] In some embodiments, the formulation does not include additional polymers other than one or more of the specific polymers described herein.
[0182] In certain embodiments, the preparation is essentially composed of protein, buffer and polymer herein. In certain embodiments, the preparation is essentially composed of protein, buffer, polymer herein and surfactant. In certain embodiments, the preparation is essentially composed of protein, buffer, polymer herein, surfactant and salt. In certain embodiments, the preparation is essentially composed of protein, buffer, polymer herein and amino acid, sugar or sugar alcohol. In certain embodiments, the preparation is essentially composed of protein, buffer, polymer herein, surfactant and amino acid, sugar or sugar alcohol.
[0183] In some embodiments, the presence of the polymer significantly reduces the turbidity of the formulation as measured at 600 nm compared to an otherwise identical formulation but not including the polymer (see Example 2 below). In some embodiments, the presence of the polymer reduces the viscosity of the formulation at 25° C. and a shear rate of 1000 1 / s compared to an otherwise identical formulation but not including the polymer (see Example 3 below). In some embodiments, the turbidity and / or viscosity is reduced compared to a formulation in which the polymer is replaced by an equal concentration of a surfactant such as PS20.
[0184] V. Testing of Protein Preparations
[0185] In some embodiments, different members of the polymer library, for example, members with different molecular weights or lengths and different monomer ratios or different monomer selections, can be placed in the holes of a microporous plate, for example, filled with a protein solution for testing. According to this method, a series of polymers are obtained, for example, these polymers have different monomer ratios and / or different monomer groups, and different lengths (corresponding to different molecular weights). In some cases, side chain or straight chain polymers can also be compared. For example, using a 96-well plate or similar porous plate, the impact of various polymers on a specific protein formulation compared to a control formulation can be tested.
[0186] For example, in a microwell plate, the effects of polymers of different composition ratios or different monomers and polymers of different lengths or molecular weights on protein stability, viscosity, turbidity, precipitation, microthermophoresis, and surface tension can be considered. For example, turbidity can be assessed by absorbance at a wavelength of 600 nm. And exemplary assays are described in Example 2 below. Viscosity can be measured, for example, in a rheometer at a specific temperature and shear rate. (See Example 3 below.) The extent of polymer-protein interaction can also be measured by microthermophoresis for various polymer or protein concentrations, as described in Example 4 below.
[0187] Examples
[0188] The present disclosure will be understood in more detail with reference to the following examples. However, they should not be construed as limiting the scope of the present disclosure.
[0189] Example 1. Materials and methods
[0190] A. Materials
[0191] Reagents were purchased from Sigma Aldrich, VWR or Fisher Scientific and were used without purification unless otherwise specified. Monomers were passed through alkaline alumina prior to polymerization to remove inhibitors. mAb-G was expressed in a Chinese hamster ovary (CHO) cell line. Sodium phosphate and histidine chloride buffers were prepared using pharmacopeia grade (USP, NP, EP) chemicals and MilliQ water. mAb-G was concentrated and buffer exchanged using Millipore (Billerica, MA) Amicon Ultra centrifuge tubes (10 or 30 kDa molecular weight cutoff, MWCO). mAb-G solutions were filtered through Corning 0.22 μm polyethersulfone (PES) vacuum filters (Corning, NY) or MilliporeSigma MillexGV 0.22 μm polyvinylidene fluoride (PVDF) filters (Burlington, MA) prior to the experiment. Pierce Bradford assay (Bradford assay) kits were purchased from ThermoFisher Scientific. Jurkat cells were purchased from ATCC (TIB-152, clone E6-1, lot #70044353).
[0192] B. Polymer Library Synthesis
[0193] The polymer library was synthesized using a chain transfer (i.e., polymerization) reaction. The liquid monomer was passed through basic alumina to remove polymerization inhibitors (e.g., hydroquinone monomethyl ether (also known as p-methoxyphenol or MeHQ)) present in the stock solution. Stock solutions of monomer, chain transfer agent (CTA), and catalyst were prepared in DMSO. The corresponding volumes of stock solutions and DMSO were transferred to a 96-well plate and the plate was sealed with tape.
[0194] The polymer consists of methyl methacrylate (MMA), oligo(ethylene glycol) methyl ether methacrylate (OEGMA), isobutyl methacrylate (IBMA) and dimethylamino methacrylate (DMAEMA). The monomer composition ranges from 5% to 50 mol% of the polymer and the monomer molecular weight ranges from 3 kDa to 20 kDa.
[0195] The polymer is prepared according to the following monomer molar ratios MMA:OEGMA:IBMA:DMAEMA:Poly 1=5:2.5:2:0.5, Poly 3=2:5:2:1, Poly 5=5:2.5:1:1.5, Poly 7=5:3:2:0, Poly 9=3:5:2:0, Poly 11=4:4:1:1) Other monomers used: (4-hydroxyphenyl)methacrylamide (10 to 20 mol%), 2-hydroxyethyl methacrylate (20 to 25 mol%), [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide (zwitterionic monomer, 10 to 25 mol%), and it is planned to try arginine methacrylate and 2-aminoethyl methacrylate hydrochloride.
[0196] In the first polymer library (in Example 2 below), polymers are synthesized to obtain a length range of 3kDa to 15kDa (measured in average molecular weight). For example, Poly1 is prepared, which has a MMA:OEGMA:IBMA:DMAEMA molar ratio of 5:2.5:2:0.5, and the average molecular weight range is designated as A to H from the smallest to the largest. Therefore, for example, Poly1 is prepared, and its average molecular weight is 3kDa (Poly1A), 7kDa (Poly1D), 8.5kDa (Poly1E), 10kDa (Poly1F), wherein the molecular weights of Poly1B and Poly1C are between the molecular weights of Poly1A and Poly1D, and Poly1G has a molecular weight higher than the molecular weight of Poly1F. For each of polymers Poly3, Poly5, Poly7, Poly9 and Poly11, a similar range of average molecular weight polymers is prepared.
[0197] To produce different polymer lengths, the molar ratio of CTA to total monomers was controlled as follows, assuming 85% conversion of monomers to polymers: A 28:100; B 16:100, C 11:100, D 8:100, E 6:100, F 5:100, and G 4:100.
[0198] Separate reactions using different monomer ratios and for producing polymers with different lengths or molecular weights are placed in separate wells of a 96-well plate.
[0199] Synthesis of CN-(3-Methacrylamidopropyl)guanidine hydrochloride (ArgMAm)
[0200] ArgMAm was synthesized via a slightly modified protocol reported previously (Funhoff et al., 2004). In a round-bottom flask under N2, N-(3-aminopropyl)methacrylamide hydrochloride (0.5 g, 2.8 mmol, 1 mol equiv.), 1H-pyrazole-1-carboxamidine monohydrochloride (0.41 g, 2.8 mmol, 1 mol equiv.), triethylamine (TEA) (0.9 mL, 6.7 mmol, 2.4 mol equiv.) and inhibitor hydroquinone (5 mg) were dissolved in dimethylformamide (DMF) (8 mL). The reaction was stirred at room temperature (21 °C) for 24 hours. The solution was poured into 50 mL of cold diethyl ether and the oil was decanted. The oil was washed twice with 10 mL of acetonitrile and once with 5 mL of TEA and then centrifuged. The resulting solid was washed with 15 mL of dichloromethane (DCM), centrifuged, decanted and further dried by rotary evaporation to afford 147.14 mg (29% yield). 1 H-NMR (400mHz, DMSO-d6) δppm: 8.03 (t, J = 5.6Hz, 1H), 7.75 (t, J = 5.9Hz, 1H), 7.22 (s, 2H), 5.68 (p, J = 1. 1Hz, 1H), 5.33 (p, J = 1.6Hz, 1H), 3.20–3.09 (m, 4H), 1.86 (dd, J = 1.6, 0.9Hz, 3H), 1.64 (p, J = 6.8Hz, 2H).
[0201] D. Synthesis of polymer libraries via photoinduced electron transfer reversible addition-fragmentation chain transfer (PET RAFT)
[0202] In the second polymer library (Example 3 below), polymers of the same target length were synthesized using photoinduced electron transfer reversible addition-fragmentation chain transfer (PET RAFT). Each polymer in the library was intended to include the same length, as indicated by the same volume of chain transfer agent and polymerization catalyst in the polymerization reactions of all polymers in the library.
[0203] Stock solutions of monomer (1 M), chain transfer agent (CTA) (0.2 M) and zinc tetraphenylporphyrin (ZnTPP) catalyst (8 mM) were prepared in dimethyl sulfoxide (DMSO). The corresponding volumes of stock solutions and DMSO were transferred to a 96-well plate (Table 1) and the plate was sealed with a plate tape. Polymerization was initiated with a white 5k LED light and allowed to proceed for 3 to 18 hours. Polymerization was terminated by removing the plate from the light source. The polymer was purified by microdialysis against water in a 96-deep well plate (Thermo Scientific, Pierce 3.5 kDa MWCO) for at least 2 days, changing the dialysate 5 times. Representative 1H-NMR Poly1 (400 mHz, DMSO-d6) δ ppm: 4.15-3.88, 3.82-3.59, 3.57-3.48, 3.48-3.37, 3.29-3.19, 2.26-2.11, 2.11-1.58, 1.52-1.37, 1.37-1.20, 1.20-1.07, 1.02-0.84, 0.84-0.60. Representative M obtained by GPC n Poly1 (polystyrene standard) 10.1 kDa, D=1.12.
[0204] The second polymer library of Example 3 was prepared as shown in Table 1 below:
[0205]
[0206] The polymerization was initiated with a white 5k LED light. The polymerization was allowed to proceed for 3 hours. The polymerization was terminated by removing the 96-well reaction plate from the light source. The polymer was purified by microdialysis in a deep 96-well plate with water or buffer for 2 days. The dialysate was exchanged 5 times.
[0207] Each polymer from the library corresponding to a specific monomer selection and monomer ratio and a specific average molecular weight is thus present in a specific well of a 96-well plate for subsequent testing.
[0208] E. Nuclear Magnetic Resonance (NMR) Spectroscopy
[0209] Nuclear magnetic resonance (NMR) spectroscopy was carried out on a 400MHz Bruker NMR instrument. Gel pore chromatography (GPC) was carried out on an Agilent 1200 series equipped with a Wyatt Optilab T-rEX RI detector and a series of 3Waters Styragel columns (HR 0.5, HR 2, HR 4), wherein tetrahydrofuran (THF) was used as eluent, and flow rate was 1 mL / min, and polystyrene conventional standards (Agilent EasiVial PS-M calibration standards). SoloVPE (C Technologies) was used to be connected to a Cary 60UV-vis (Agilent), and extinction coefficient was used at 278nm to determine protein concentration by variable path length ultraviolet-visible (UV-vis) spectroscopy. Absorbance precipitation assay and fluorescence measurement were carried out on a Biotek Synergy Neo2 multi-mode reader.
[0210] F. Microscale Thermophoresis (MST)
[0211] MST was performed on a Nanotemper Monolith NT automated instrument with Premium Coated capillaries at a polymer concentration of 15.5 μM and mAb-G at a concentration of 2 x 10 -7 Up to 1x 10 -4 M. measured changes in the fluorescence of the polymer upon heating in a capillary.
[0212] G. Isothermal Titration Calorimetry (ITC)
[0213] ITC was performed on a TA Instruments Nano ITC with a titration syringe volume of 50 μL and a starting cell volume of 450 μL, 25 injections of 2 μL. mAb-G (100 μM) and Poly1 (500 μM) were in 15 mM phosphate buffer pH 7.4. SCISSOR experiments were performed on a Sirius (now Pion) SCISSOR system.
[0214] H. Dynamic Light Scattering (DLS)
[0215] DLS was performed in half-area 96-well plates on a Wyatt Dynapro plate reader at 25°C with a polymer concentration of 0.1 w / v%. Live / dead cell counts were measured using Countess 3FL (Invitrogen).
[0216] I. Polymer Turbidity / Sedimentation Determination
[0217] Sample monoclonal antibody proteins (e.g., mAb G) for testing were buffer exchanged into 15 mM sodium phosphate buffer pH 7.4. In a 96-well plate, water (control) or polymer / excipient stock solutions were added to give a final formulation containing 1.6 μM polymer and 80 mg / mL protein with 15 mM sodium phosphate, pH 7.4.
[0218] Another protein sample was diluted in the same volume of phosphate buffer pH 7.4, but with 100 mM sodium chloride or without sodium chloride as a control sample. A control formulation including DMSO instead of sodium chloride and with buffer only was also prepared.
[0219] The samples were pipetted into a 96-well plate to give a total volume = 100 uL). The plates were incubated at 4°C ambient conditions for 18 hours and turbidity was measured by absorbance at 600 nm. Measurements were recorded for a period of time starting after the above incubation or after 24 hours of incubation. The samples were removed from the plate after the assay and centrifugation and observed for any precipitate formation to determine to what extent the presence of the polymer allowed the protein to remain suspended in solution and prevented the protein from precipitating during storage (since any precipitate should be composed of protein without the polymer).
[0220] Turbidity measurements using mAb G are shown in Table 2 below (Example 2), where solution turbidity is compared to mAb G in 100 mM NaCl (rightmost column shows p-values vs. mAb G w / salt). Samples contained 80 mg / mL mAb G in 15 mM phosphate buffer at pH 7.4 and 1.6 μM polymer at indicated locations. Samples were measured after incubation at 4°C for 18 hours as described above.
[0221] Turbidimetric measurements using mAb-G are described in Example 3 below.
[0222] In some of the examples described below, measurements were recorded at 25°C or 37°C instead of 4°C.
[0223] J. Polymer Viscosity
[0224] Polymer viscosity was measured using a cone-disc rheometer set at 25° C. Polymer, excipient, or water (control) was added to each protein sample with final excipient concentrations ranging from 0.02% to 0.1% (w / v).
[0225] K. Surface tension (ST)
[0226] Use a hanging drop tensiometer to measure the surface tension of solutions with polymer or PS20 and water controls. Prepare 0.02% (w / v) of polymer Poly1F in water. Prepare 0.05% (w / v) PS20 in water. The tensiometer measures surface tension (ST) by recording the image of each drop formed by the test solution. The tensiometer software calculates ST based on the shape of each drop. Each drop is allowed to stand for 30 minutes after its formation so that the measurement is recorded when the drop is in equilibrium. Measure in triplicate and calculate the average ST.
[0227] L. Absorbance-based high-throughput precipitation assay
[0228] mAb-G buffer was exchanged into 15mM sodium phosphate buffer pH 7.4 and filtered. In a 96-well plate, water (control) or polymer stock solution (20% w / v in water) was added to obtain a 0.15% (w / v) solution when protein was added. mAb-G was diluted to a final concentration of 80mg / mL in the well with sodium phosphate buffer pH 7.4 containing NaCl, making the final salt concentration in the well 150mM. A salt-free control was also prepared in a similar manner. The solution in the tube was fully mixed and filtered on a roller. The solution was pipetted into a 96-well plate containing aliquots of polymer excipient stock solution or water, with a total volume of 100 μL. The plate was sealed, incubated at 25°C, and turbidity was measured by absorbance at 600nm every 2 hours for 46 hours.
[0229] M. Low-throughput Eppendorf LoBind tube precipitation assay
[0230] mAb-G buffer was exchanged into 15mM sodium phosphate buffer pH 7.4 and filtered. mAb-G was diluted to a final concentration of 80mg / mL in a tube with sodium phosphate buffer pH 7.4 containing NaCl, so that the final salt concentration in the well was 150mM. A salt-free control was also prepared in a similar manner. The solution in the tube was fully mixed on a roller. In a series of tared Eppendorf LoBind tubes, polymer stock solution or water (control) and mAb-G solution were added to make a total volume of 200 μL. The tube was incubated in an incubator at 37°C and taken out regularly for analysis. The tube was centrifuged at 3200x g for 2 minutes, decanted and lyophilized. As described in the analytical technique section, the soluble protein concentration was measured by SoloVPE, and the weight of the precipitate after lyophilization was measured.
[0231] N. FITC labeling of Poly1
[0232] FITC-maleimide was conjugated to the polymer by aminolysis of trithiocarbonate followed by maleimide-thiol coupling. Poly1 (200 mg / mL, 50 μL) was dissolved in water in an Eppendorf tube. Tris(2-carboxyethyl)phosphine (TCEP) (30.71 mg) dissolved in 100 μL of water was added, followed by 20 uL of ethanolamine. The reaction was mixed on an oscillator for 2 hours. FITC-maleimide (3.05 mg, 5 equivalents) was dissolved in 100 μL of 15 mM phosphate pH 7.4 buffer and 80 μL of DMF and added to the reaction mixture. The reaction was mixed for another 2 hours, then the polymer was purified for 2 days by dialysis against water (Pierce Slide-A-Lyzer dialysis cassette, 3 kDa MWCO). FITC (494 nm, 68,000 M -1 cm -1 ) and Poly1(420nm,69,400M -1 cm -1 The degree of labeling (DOL) was calculated using the molar extinction coefficient of , a correction factor of 0.3, and the absorbance of the labeled polymer at wavelengths of 494 nm and 420 nm (Equation 1).
[0233]
[0234] Among them A 494 and A 420 is the absorbance at 494nm and 420nm, ε FITC ε Poly1is the molar extinction coefficient of FITC and Poly1 at their respective wavelengths. DOL 0.23568.
[0235] O.SCISSOR System Solubility and Pharmacokinetic (PK) Determination
[0236] The SCISSOR experiment was performed with minor modifications as described in the literature (Bown et al., 2018a). The chamber was loaded with 300 mL of SCISSOR buffer, which contained 6.4 g NaCl, 0.09 g MgCl2·6H2O, 0.4 g KCl, 0.2 g CaCl2, and 2.1 g NaHCO3 per 1 L of Milli-Q water, equilibrated to 34 °C with CO2 and maintained at pH 7.4. The SCISSOR cartridge was loaded with 5 mL of 6.25 mg / mL 1.38 MDa hyaluronic acid (HA) dissolved in phosphate buffered saline (PBS) pH 7.4 and kept approximately 1 cm above the bottom of the cartridge holder (above the clamp) so that the transmittance at the very bottom could be detected. 0.2 mL of mAb-G (80 mg / mL) was injected into the chamber at a constant rate over approximately 20 seconds using a 1 mL syringe with a 25G needle. The autosampler was set to collect samples at 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330, 360 and 390 minutes after injection. Fluorescence measurements (100 μL sample in a black 96-well plate, λ ex =490nm,λ em =555 nm) to complete the offline analysis of the collected samples. Bradford assay was performed according to the manufacturer's description of the microplate procedure (96-well plate, 150 μL sample, 150 μL reagent, A 595nm ). Photographs of the cartridge were also taken through the chamber window during the experiment to visualize any sediment.
[0237] P. Intrinsic fluorescence
[0238] In a 96-well plate, 100 μL of 1 mg / mL mAb-G stock solution and 100 μL of polymer stock solutions of different concentrations (5 mol to 100 mol equivalents) were mixed in 15 mM phosphate buffer pH 7.4 (n=3 for each polymer concentration). Controls of polymers without buffer and buffer alone were also included and used as background subtraction. The plate was briefly centrifuged (20 seconds, about 150 x g), and 50 μL of each solution was transferred to a black 384-well plate. The plate was briefly centrifuged (20 seconds, about 150 x g) and fluorescence (λ) was measured. ex=295nm,λ em =340 nm). In addition, the absorbance at 295 nm and 340 nm was measured. Calibration and control experiments were included as described in the literature (vande Weert & Stella, 2011a). In summary, the absorbance measurements were used to correct for the inner filter effect (Equation 2).
[0239]
[0240] where F obs and F corr are the measured and corrected fluorescence, A ex and A em is the absorbance value and emission wavelength during excitation, and d ex and d em is the path length in cm. The path length in the well is estimated using the well dimensions and the volume of the sample in the well (0.2 cm).
[0241] The quenching constant k was calculated by using the Stern-Volmer equation (Eq. 3) q , and it was also confirmed that the fluorescence reduction was not due to collision quenching.
[0242]
[0243] where F is the fluorescence at a given polymer concentration [L], F o is the fluorescence in the absence of polymer, and τ is the fluorescence lifetime of tryptophan (1-10 ns). The quenching constant is 1.02×10 12 M -1 s -1 , which is larger than 2×10 for collision quenching process 10 M -1 s -1 .
[0244] Q. Detection of cell viability of Jurkat cells by trypan blue assay
[0245] Jurkat cells were passaged 4 times in RPMI 1640 medium (10% FBS, 1% PenStrep) and incubated at 37°C, 95% humidity and 5% CO2. The cells were centrifuged and plated at 4.4×10 6 In a sterile 24-well plate, add 100 μL of cell suspension to each well to make the final cell concentration 8x10 5Cells / mL. Poly1 was diluted in culture medium and sterile filtered. 400L Poly1 solution or culture medium was added to each well (n=4). Cells were incubated for 24 hours and cell viability was assessed by trypan blue assay. Trypan blue was added to suspended cells at a ratio of 1:1 and the live / dead % of cells were counted. Cell viability was calculated by normalization to a control without additives.
[0246] Example 2. Libraries comprising polymers of different lengths
[0247] Several monomers were selected for various intermolecular interactions (see Figure 1 ). Two hydrophobic monomers, methyl methacrylate (MMA) and isobutyl methacrylate (IBMA), were chosen to impart hydrophobic interactions, but with slightly different molecular weights. Two hydrophilic monomers were chosen. Oligo(ethylene glycol) methyl ether methacrylate 500 Da (OEGMA 500 ) as a hydrogen bond acceptor and to impart water solubility. Dimethylaminoethyl methacrylate (DMAEMA) was selected as a positively charged monomer to target the interaction with the negative film in mAb. From these monomers, polymers Poly1, Poly3, Poly5, Poly7 and Poly9 were prepared, each with different lengths, designated by letters after the polymer name (e.g., Poly 1A-G, Poly3A-G, etc.), from the shortest to the longest.
[0248] A. Polymer turbidity
[0249] Polymer turbidity was measured as described in Example 1. As shown in Table 2, the absorbance at 600 nm (A) was significantly higher by removing or replacing the salt with DMSO or by adding specific polymer species compared to protein in 100 mM NaCl. 600 Entries with an asterisk (*) are relevant controls and samples that are statistically significantly different from the positive control, particularly Poly1D, Poly1F, and Poly7D.
[0250]
[0251] Further data are shown in Figures 2A to 4 and FIG. 7A to FIG. 7B middle. FIG. 2A to FIG. 2B The following conditions are shown including 80 mg / mL mAb G and 15 mM phosphate buffer, pH 7.4, and 100 mM NaCl ( Figure 2A ) or 150 mM NaCl ( Figure 2B) at 600 nm: in the presence of increasing concentrations of two different molecular weight Poly1 species Poly1D (average 7 kDa), Poly1F (average 10 kDa) and Poly7 species Poly7D (average 7 kDa), the concentration range is 0 to 0.4 mM polymer (specifically 0, 1.6, 6.6 or 33 μM; polymer concentrations of about 0.0014, 0.006 or 0.03% w / v). As shown in the panels, all polymers reduced the absorbance at 600 nM in the 100 mM NaCl formulation, but only the two Poly1 species reduced the absorbance at 600 nm in the 150 mM NaCl formulation.
[0252] Figure 3 The precipitation kinetics of formulations with 150 mM NaCl and three different concentrations of Poly 1 E (average 12 kDa) are shown. All three concentrations of Poly 1 E were able to prevent a significant increase in absorbance at 600 nm over an incubation time of up to 32 hours at 23°C. Figure 4 The precipitation kinetics of the above formulations are shown in the presence of several different concentrations of polysorbate 20 (PS20) instead of the polymer excipient. Figure 3 to Figure 4 As shown, the presence of Poly 1 E resulted in a lower increase in absorbance over time compared to the increase in absorbance of the solution with PS20 or the control solution with no additive. Fig. 7A Shown are images of aliquots of mAb G formulations including 80 mg / mL mAb G, 15 mM phosphate buffer, pH 7.4, 150 mM NaCl, and no additional excipients (left), increasing concentrations of Poly 1 E (middle), and increasing concentrations of PS20 (right). Figure 7B Aliquots of formulations including PS20 excipient (left) or Poly1E excipient (right) are shown after centrifugation to separate the precipitant. Figure 7B It is apparent that after centrifugation, there is significantly more insoluble precipitate in the preparations including PS20 than in the preparations including Poly 1E.
[0253] B. Polymer Viscosity
[0254] The polymer viscosity was measured as described in Example 1. The viscosity data are provided in FIG. 5A to FIG. 6 middle. Figure 5A The viscosity change (in cP) of mAb G solution at 195 mg / mL mAb G in 15 mM histidine chloride buffer at 25°C, pH 5.5 with either Poly 1D or PS20 excipients is shown as the concentration of the formulation increases from 0% w / v to 0.1% w / v. Single point viscosity was measured at a shear rate of 1000 1 / s. Figure 5A As shown, Poly1D is more effective than PS20 in reducing viscosity. Figure 5B Shown is the extent of viscosity reduction following addition of 0.02% w / v Poly 1D alone, 0.05% w / v PS20 alone, or a combination of 0.02% w / v Poly 1D and 0.05% PS20. While the changes were similar for each polymer alone, the addition of both polymers resulted in a further reduction in viscosity.
[0255] Figure 6 The dependence of viscosity on shear rate for 194 mg / mL mAb G in 15 mM histidine chloride buffer at pH 5.5 at 25°C for shear rate ramps from 10 to 10000 1 / s is shown to assess the effect of shear rate on viscosity. As shown, without PS20 or Poly1D, mAb G formulations show reduced viscosity when shear rate increases between about 10 1 / s and 100 1 / s. The presence of PS20 or Poly1D eliminates such dependence, indicating that both excipients are surface active. A shear rate of 1000 1 / s was selected for the next set of experiments.
[0256] The effects of excipients on the viscosity of various protein preparation samples are shown in Tables 3 and 4. Figures 9 to 12 The concentration of each sample monoclonal antibody protein mAb G, B, C and E and Fab fragment Fab G ranged from 194 mg / mL to 207 mg / mL in 15 mM histidine chloride pH 5.5. The concentration of each polymer in the library was 33 μM (ie 0.03%).
[0257] The antibody species tested were as follows: mAb G, mAb B, mAb C, and mAb E were monoclonal IgG antibodies, mAb D was a bispecific scFv monoclonal antibody, and Fab G was a Fab fragment.
[0258] Viscosity was measured in 30 mM HisCl with and without 0.15% (w / v) of the polymer in the pool. Figures 9 to 12 In , the average relative % change in viscosity with polymer (% change normalized by initial viscosity w / o addition) is plotted by polymer composition (for several monomers) and polymer identity.
[0259] Based on the mechanism driving high viscosity, mAbs are classified as electrostatic or hydrophobic. For example, for solutions of mAb G, mAb E, and mAb C, hydrophobic protein-protein interactions are believed to drive viscosity changes, as shown in Table 3. For example, for solutions of mAb B and Fab G, electrostatic interactions are believed to drive viscosity changes, as shown in Table 4. In general, these tables show a greater decrease in viscosity in the presence of polymer excipients, where viscosity is driven by hydrophobic interactions.
[0260]
[0261]
[0262]
[0263] C. Microscale Thermophoresis (MST)
[0264] The molecular interactions between the polymer and several proteins were measured using microscale thermophoresis (MST), a method for calculating the fraction of proteins bound to the polymer. MST was performed as described in Example 1 above. Fig.10 As shown, four different proteins in a formulation including Poly 1F displayed different degrees of molecular interactions with increasing polymer concentration.
[0265] Example 3. A library comprising a series of polymers of the same length and different monomer contents
[0266] A second polymer library (Table 1; Figure 1 This technique has previously been used to prepare polymers in a high-throughput manner without the rigorous degassing required by other controlled radical polymerization techniques and can be achieved at room temperature using photocatalysts to initiate polymerization with visible light (Gormley et al., 2018; Ng et al., 2018).
[0267] Again, three hydrophilic monomers were selected, one neutral and two charged. Oligo(ethylene glycol)methyl ether methacrylate 500 Da (OEGMA 500) as hydrogen bond acceptors and convey water solubility. Dimethylaminoethyl methacrylate (DMAEMA) and the arginine-mimicking monomer N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm) were selected as monomers with positive charges at pH 7 to 4 (Funhoff et al., 2004; Laaser et al., 2015; Lee et al., 2011) to promote electrostatic interactions with negative patches on the mAb surface and / or increase electrostatic repulsion between mAbs. In addition, ArgMAm was selected as an arginine mimetic because arginine is an excipient and is often used as a buffer component, and arginine reduces viscosity when added as an excipient in many protein formulations (Shukla & Trout, 2010; Sudrik et al., 2017). The library was designed to explore MMA, OEGMA, and other positively charged monomers at pH 7 to 4 (Funhoff et al., 2004; Laaser et al., 2015; Lee et al., 2011). 500 , IBMA and DMAEMA or ArgMAm, while targeting the solubility of the final polymer in aqueous solution, the composition includes 2 to 4 monomers. Polymerization was confirmed by GPC with 3 randomly selected polymers. The molecular weight of the polymer described herein is about 10 kDa. n (Representative Poly1 M n 10.1 kDa, D = 1.12, Poly7 M n 11.3kDa, D=1.22, Poly22 M n 12.3 kDa, D=1.11). The polymer was purified by microdialysis in water for 3 days in the same 96-well format and the elimination of DMSO and reactant impurities was confirmed by HPLC ( FIG. 13A to FIG. 13B ).
[0268] A. Polymer turbidity
[0269] The effect of polymers from the second library on mAb-G precipitation was investigated using a high-throughput turbidity screening assay based on visible light absorbance (as described in Example 1 above). In preliminary experiments, the best sensitivity to protein precipitation with minimal background was observed by measuring absorbance at 600 nm ( FIG. 14A to FIG. 14B ). The protein buffer was exchanged to 15 mM phosphate buffer pH 7.4 because the protein does not precipitate at low ionic strength at this pH. 150 mM sodium chloride (NaCl) and 0.15% heteropolymer excipient stock solution were added. The absorbance was monitored at 600 nm to quantify the precipitation of the mAb. The absorbance versus incubation time is plotted in Figure 2. Fig.15 and FIG. 16A to FIG. 16D Three properties of precipitation kinetics were quantified: precipitation onset time (t onset ), total area under the curve (AUC) and maximum absorbance (A max). Qualitative ranking compared to controls highlights promising polymer candidates ( Fig.17 ). Several polymers with two or more white or no light grey attributes were selected as leads for further analysis.
[0270] Characterization of the precipitation under relevant temperature conditions was accomplished by a low-throughput, high-volume approach in Eppendorf tubes to reduce evaporation artifacts observed in disk-based UV-Vis spectrometry at temperatures above 25°C (data not shown). mAb-G, NaCl solution, and polymer solution prepared in 15 mM phosphate buffer pH 7.4 were added to a series of tubes, and the concentration of mAb-G in the supernatant after centrifugation and the weight of the dried precipitate were measured at specified time intervals. Surprisingly, most of the polymers selected from the screen did not improve the solubility of mAb-G ( FIG. 18A to FIG. 18B ). In one case, at higher concentrations of polymer (Poly11), precipitation was faster than without the additive. Changes in temperature and polymer concentration may play an important role in how excipients affect the precipitation kinetics of mAb-G at 37°C, but at 25°C, the three “white” properties (i.e. Fig.17 The values in the white box indicate a great improvement in the precipitation kinetics). Although 1% Poly1 did not improve the precipitation ( FIG. 18A to FIG. 18B ), but when added at 0.15%, 0.15% Poly1 improved precipitation by a statistically significant amount compared to no addition within the first 48 hours of the experiment ( Fig.19A ). Higher concentrations of polymer may lead to steric crowding of mAb, overwhelm any beneficial effects. In addition, both Poly22 and Poly11 are less hydrophobic than Poly1, which may lead to their different effects on mAb-G precipitation compared to Poly1. Based on these results, 0.15% Poly1 was selected for continued evaluation.
[0271] B. Polymer Viscosity
[0272] It is assumed that the in vivo protein concentration during subcutaneous (sc) injection will gradually decrease as the mAb diffuses from the injection site. It is expected that the addition of polymers may prevent injection site reactions caused by protein precipitation, provided that the protein concentration drops below the solubility limit before the precipitation time. In order to more comprehensively evaluate the effects of precipitation and changes in mAb-G concentration due to diffusion in vitro, the SCISSOR system (as described in Example 1) was used, an instrument developed for in vitro evaluation of sc mAb pharmacokinetics (PK). The system uses a sample cartridge containing hyaluronic acid (HA) in a buffer, in which the dialysis membrane is tuned to simulate mAb scPK in humans (Bown et al., 2018a; Kinnunen et al., 2015). The pH and temperature of the device are also monitored and controlled. It is able to measure the linear transmittance percentage of the cartridge throughout the experiment and automatically remove aliquots from a large volume container for offline analysis. Interestingly, during the initial experiment, mAb-G precipitation was observed immediately after injection, which is contrary to previous in vitro experiments, in which mAb precipitation was observed after several hours. This may be due to steric crowding and the increased viscosity of the HA matrix used. FIG. 20A to FIG. 20B ) to calibrate the injection volume, which we observed from in vivo experiments to be the highest concentration that did not cause inflammation at the mAb-G injection site in vivo (data not shown). Future experiments investigating the effects of the cartridge matrix on precipitation may improve this model to assess precipitation, as cartridge conditions were developed to correlate with mAb PK in humans and do not necessarily reflect the physiological composition of the sc space.
[0273] First, the precipitation and PK of mAb-G without any additives were measured by linear transmittance, offline protein concentration quantification via Bradford assay, and recording of the cartridge image through the cell window. After injection of mAb-G into the cartridge, protein precipitation occurred, as evidenced by the transmittance of the bottommost channel (channel 4) decreasing to 60% within 5 minutes ( Fig.19C ) and barrel image ( Fig.19D ). When mAb-G was formulated with 0.15% Poly11, the extent of precipitation was reduced, as shown in the barrel image ( Fig.19D ). The transmittance data from channel 4 increased to about 80% within 5 minutes ( Fig.19C ), demonstrating a reduced degree of precipitation. The release of mAb-G from the cartridge measured by Bradford assay showed similar initial release rates with and without Poly1 ( Fig.19F), the total amount of mAb-G released was slightly less when Poly1 was present. Note that the total amount of mAb-G released was only statistically significantly different after approximately 270 minutes (p<0.05). This difference may be due to protein-polymer interactions that can alter the diffusion of mAb-G and its interaction with the HA matrix. In addition, the PK of the polymer alone was analyzed using the polymer fluorescently labeled with FITC. The polymer was cleared faster than mAb-G ( Figure 19G ), as expected due to its low molecular weight (10 kDa). However, the release rate also suggests that there is an interaction between the slightly positively charged polymer and the negatively charged HA matrix. The higher error in the replicates could be due to the heterogeneity of the micelles formed by the self-assembly of the random heteropolymers due to their amphiphilic nature, as shown by DLS ( Fig. 27 ).
[0274] Example 4. Properties of Poly1
[0275] A. Poly1 as a surfactant
[0276] The mechanism by which the polymer improves colloidal stability was also investigated. Because the polymer comprises a mixture of hydrophobic and hydrophilic monomers, it is hypothesized that the polymer has the potential to act as a surfactant and form micelles. The surface tension (ST) measured by a hanging drop tensiometer (as described in Example 1 above) is consistent with this hypothesis. By measuring ST at several polymer concentrations, it was found that the critical micelle concentration (CMC) of Poly1 is between 0.002% and 0.02% ( FIG. 28A to FIG. 28D ). Poly1 above its CMC reduced the ST of water from 72 to 40.3 mN / m, which is similar to the ST reduction observed with polysorbate 20 (PS20) above its CMC (Mittal, 1972) (Table 4). Interestingly, Poly1 altered the precipitation kinetics in the disk-based absorbance assay, whereas PS20 did not ( FIG. 16A to FIG. 16D ). Therefore, we hypothesize that there are additional mechanisms at work in this system.
[0277]
[0278] B. Microscale Thermophoresis (MST)
[0279] The interaction of Poly1 with mAb-G through intermolecular interactions (including electrostatic interactions, hydrogen bonds, and hydrophobic / van der Waals interactions) was evaluated. To evaluate the binding of Poly1 to the protein, several methods were used. First, microscale thermophoresis (MST; as described in Example 1 above) was initially used to evaluate the binding of Poly1 to mAb-G because of its sensitivity to changes in the interaction and small volume requirements ( Fig.21A) (Jerabek-Willemsen et al., 2011). A constant Poly1 concentration was used as the amount of protein increased, and an estimated dissociation constant (K d )>0.5 mM. For protein solubility and viscosity above 1 mM, no complete binding curves with true quantification of binding were obtained.
[0280] C. Isothermal Titration Calorimetry (ITC)
[0281] Next, isothermal titration calorimetry (ITC; as described in Example 1 above) was also used to assess the enthalpy of binding interaction ( Fig.21B The viscosity of mAb-G above 1 mM and the viscosity of Poly1 above 100 μM will prevent the generation of a complete ITC binding curve ( Fig.23 ). However, the millimolar concentration used indicates the order of magnitude of the interaction. For redundancy, the enthalpy of binding was determined by measuring the enthalpy of de-micelleization and the critical micelle concentration (CMC) (Bam et al., 1998). The total heat of de-micelleization, polymer dilution and protein-polymer binding was determined based on the heat released during the polymer titration into the buffer solution and mAb-G solution. The CMC estimated by this technique was 0.01mM (0.01%), which is consistent with the ST measurement value (Table 4). The selected concentration that changes the precipitation kinetics of mAb-G exceeds the CMC to ensure that the bulk has sufficient polymer concentration relative to the surface. The binding enthalpy of the polymer to mAb-G calculated from the change in the initial slope of the polymer titration into mAb-G is approximately -0.18kcal / mol, indicating that there is a weak interaction between the two substances. The endothermic binding indicates that entropy-driven binding may be due to hydrophobic interactions and the release of bound "structured" water (Ladbury & Chowdhry, 1996). As expected, the intrinsic fluorescence decreases with increasing polymer amount. The reduction in polymer molar equivalents of the order of 10 to 100 to achieve this further indicates the weak nature of this interaction. To ensure that the reduction in fluorescence was due to binding and not to artifacts caused by inner filter effects or collisional quenching (van de Weert & Stella, 2011a), control experiments were performed as detailed in Example 1. Assuming 1:1 binding, the association constant (K) was calculated from the slope of the Stern-Volmer plot. a )( Fig.21D ), and the corresponding K d It was estimated to be about 0.9 mM, which is of the same order of magnitude as the MST result.
[0282] D. Intrinsic fluorescence of Poly1
[0283] Finally, intrinsic fluorescence quenching (as described in Example 1 above) was used to qualitatively confirm the results of the other two techniques ( FIG. 21C to FIG. 21D Intrinsic tryptophan fluorescence was measured in the presence of increasing concentrations of Poly1 ( Fig. 21C ). As expected, the intrinsic fluorescence decreased with increasing amounts of Poly 1. This decrease was achieved on the order of 10 to 100 molar equivalents of Poly 1, again indicating the weak nature of this interaction. To ensure that the decrease in fluorescence was due to binding and not an artifact of inner filter effects or collisional quenching as described by van de Weert and Stella, control experiments were included as detailed in the Methods and Materials (van de Weert & Stella, 2011b). Assuming 1:1 binding, the association constant (K) was calculated from the slope of the Stern-Volmer plot. a )( Fig.21D ), and the corresponding K d It was estimated to be about 0.9 mM, which is of the same order of magnitude as the MST result.
[0284] E. Summary of the interaction between Poly1 and mAB-G
[0285] From biophysical studies, including Poly1 may alter mAb-G precipitation via binding equilibrium. Similar studies investigating viscosity reduction via reversible PEGylation of high-concentration mAb formulations also showed that PEG binding to many proteins in a short period of time disrupts mAb self-interactions (Gong et al., 2019). PEG binding to many proteins in a short period of time disrupts mAb self-interactions (Gong et al., 2019). Binding experiments using surface plasmon resonance (SPR) require high concentrations (100 mM) of mPEG-phenylglyoxal to generate association / dissociation curves, similar to the increasing concentrations required to measure binding in this report. For the random heteropolymers described here, molecular weight, binding strength, number of binding sites, and other mechanisms such as micellization also contribute to the precipitation inhibition mechanism.
[0286] F. Cytotoxicity of Poly1
[0287] In some cases, the polymer excipients described in the examples herein can be used in pharmaceutical preparations, such as pharmaceutical proteins, including antibodies, and subcutaneous (sc) preparations that may require high protein concentrations. Therefore, Poly1 toxicity was studied in vitro. Because Poly1 is a surfactant, the membrane integrity of the cells was used as a measure of cytotoxicity determined using trypan blue. Jurkat cells were used to simulate toxicity to immune cells and were used as a suspension cell line because of their ease of experiment. Addition of all tested concentrations of Poly1 did not significantly change cell viability ( Fig. 22). The immunogenicity, biocompatibility, and bioaccumulation of polymers are also considerations for the development of new polymer excipients for pharmaceutical formulations. Immune responses to polymers are generally thought to be caused by flexibility and regular repeating structures. The polymers described herein contain relatively randomly distributed monomers, making them superior to other polymers. Anti-PEG antibodies have been observed in some PEG-containing products and bioconjugates (Kozma et al., 2020; Zhang et al., 2016). However, OEGMA 500 The length of the PEG side chain of the monomer (500Da) is less than the approximately 750Da required for binding / producing anti-PEG antibodies (Huckaby et al., 2020). Finally, the SCISSOR experiment suggests that the polymer will likely be cleared from SC tissue into the circulation at a rate similar to or slightly faster than mAb-G. In addition, the polymer reported here is approximately 10kDa, which is less than the approximately 30kDa molecular weight limit for renal clearance associated with PEG (Bertrand & Leroux, 2012). Therefore, the polymer is expected to be removable.
[0288] discuss
[0289] As described in the examples herein, a random heteropolymer library is synthesized and the ability of the polymer in the library to improve the solubility of the monoclonal antibody is screened. The polymer is synthesized and purified in a high-throughput manner. The polymer is screened for the effect of the polymer on the solubility of the monoclonal antibody mAb-G using a disk-based absorbance turbidimetry assay, which precipitates under physiological pH and salt conditions. The solubilization effect of the selected polymer on mAb-G under increasingly relevant conditions (temperature, in the presence of HA as a simulated matrix) is further studied. Mechanism studies show that the polymer acts as a surfactant and can interact weakly with mAb-G, thereby changing the kinetics of precipitation. In short, random heteropolymers are a promising new type of excipient that can improve the safety and convenience of preparing high-concentration poorly soluble proteins, particularly for subcutaneous administration.
[0290] At 25℃( Fig.15 ) in the initial solubility screening, the precipitation kinetics in the presence of various polymers changed with that at 37 °C ( FIG. 18A to FIG. 18B and FIG. 19A to FIG. 19B ) have not been completely consistent. For example, at 25°C, Poly22 and Poly11 have a later t onset and lower AUC, and Poly22 has a lower AUC than Poly1 max ( Fig.15 and Fig.17 ), but at 37°C, only Poly1 prolonged the precipitation time ( FIG. 19A to FIG. 19BMoreover, only 1% Poly11 made the precipitation of mAb-G worse compared to 1% Poly1, Poly22, and Poly7, which made the precipitation of mAb-G the same as the control ( Fig.17 Among these polymers, Poly11 and Poly22 have the lowest hydrophobicity and relatively high mOEGMA 500 mole percentage, where Poly22 contains ArgMAm instead of DMAEMA. These results are consistent with ITC experiments ( Fig.21B ), suggest that hydrophobic interactions between the polymer and mAb may be important and help characterize Poly1 as the optimal polymer for improving the colloidal stability of mAb-G. The temperature dependence of the mAb-G precipitation timescale, with the slowest kinetics at around room temperature (25°C) and faster kinetics at higher temperatures (37°C), again illustrates the importance of hydrophobic interactions. This change may arise from increased structural flexibility at higher temperatures exposing more hydrophobic residues, coupled with increased desolvation resulting in greater entropy gain (Chen et al., 2003) and increased strength of hydrophobic interactions (Baldwin, 1986). Additionally, differences in diffusion rates and / or aggregate solubility may contribute to this temperature dependence (Wang & Roberts, 2018). Overall, the kinetics of the precipitation process and how random heteropolymers affect the early stages of precipitation / seeding appear to be important in this system.
[0291] In some cases, the polymer excipients described in the examples herein can be used in pharmaceutical preparations, such as pharmaceutical proteins, including antibodies, and subcutaneous (sc) preparations that may require high protein concentrations. The immunogenicity, biocompatibility, and bioaccumulation of polymers are considerations for developing novel polymer excipients for pharmaceutical preparations. Immune responses to polymers are generally believed to be caused by flexibility and regular repeating structures. The polymers described herein contain relatively randomly distributed monomers, making them superior to other polymers.
[0292] Another aspect of pharmaceutical formulation development (e.g., sc antibody formulations, etc.) is to ensure product quality during the manufacture, storage, and administration of these therapeutic agents. Precipitation observed at any of these stages (including injection) can limit the production of mAbs, especially if they are intended for sc administration or must be formulated at high concentrations. For mAbs described herein, relatively high salts and pH under physiologically relevant conditions can lead to increased non-covalent molecular interactions, resulting in precipitation (Pindrus et al., 2015). The observable differences in the precipitation kinetics of mAb-G in simulated sc matrices indicate that random heteropolymer excipients can deliver poorly soluble mAbs by sc injection.
[0293] References
[0294] Alconcel, S.N.S., Baas, A.S., & Maynard, H.D. (2011). FDA-approved poly(ethylene glycol)–protein conjugate drugs. Polymer Chemistry, 2(7), 1442–1448. doi.org / 10.1039 / C1PY00034A
[0295] Arlotta, K.J., & Owen, S.C. (2019). Antibody and antibody derivatives as cancer therapeutics. Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology, 11(5), e1556. doi.org / 10.1002 / wnan.1556
[0296] Baldwin, R.L. (1986). Temperature dependence of the hydrophobic interaction in protein folding. Proceedings of the National Academy of Sciences of the United States of America, 83(21), 8069–8072. https: / / doi.org / 10.1073 / pnas.83.21.8069
[0297] Bam, N.B., Cleland, J.L., Yang, J., Manning, M.C., Carpenter, J.F., Kelley, R.F., & Randolph║, T.W. (1998). Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. Journal of Pharmaceutical Sciences, 87(12), 1554–1559. doi.org / 10.1021 / js980175v
[0298] Bertrand,N.,&Leroux,J.-C.(2012).The journey of a drug-carrier in thebody:An anatomo-physiological perspective.Journal ofControlled Release,161(2),152–163.doi.org / 10.1016 / j.jconrel.2011.09.098
[0299] Bown,H.K.,Bonn,C.,Yohe,S.,Yadav,D.B.,Patapoff,T.W.,Daugherty,A.,&Mrsny,R.J.(2018).In vitro model for predicting bioavailability ofsubcutaneously injected monoclonal antibodies.Journal of Controlled Release,273,13–20.doi.org / 10.1016 / j.jconrel.2018.01.015
[0300] Chen,W.-Y.,Huang,H.-M.,Lin,C.-C.,Lin,F.-Y.,&Chan,Y.-C.(2003).Effectof Temperature on Hydrophobic Interaction between Proteins and HydrophobicAdsorbents:Studies by Isothermal Titration Calorimetry and the van’t HoffEquation.Langmuir,19(22),9395–9403.doi.org / 10.1021 / la034783o
[0301] Crommelin,D.J.A.,Mastrobattista,E.,Hawe,A.,Hoogendoorn,K.H.,&Jiskoot,W.(2020).Shifting Paradigms Revisited:Biotechnology and the PharmaceuticalSciences.Journal of Pharmaceutical Sciences,109(1),30–43.doi.org / 10.1016 / j.xphs.2019.08.010
[0302] Dubacheva,G.V.,Curk,T.,Mognetti,B.M.,Auzély-Velty,R.,Frenkel,D.,&Richter,R.P.(2014).Superselective targeting using multivalentpolymers.Journal ofthe American Chemical Society,136(5),1722–1725.doi.org / 10.1021 / ja411138s
[0303] Funhoff,A.M.,van Nostrum,C.F.,Lok,M.C.,Fretz,M.M.,Crommelin,D.J.A.,&Hennink,W.E.(2004).Poly(3-guanidinopropyl methacrylate):A Novel CationicPolymer for Gene Delivery.Bioconjugate Chemistry,15(6),1212–1220.doi.org / 10.1021 / bc049864q
[0304] Garidel,P.,Kuhn,A.B., ,L.V.,Karow-Zwick,A.R.,&Blech,M.(2017).High-concentration protein formulations:How high is high?European Journal ofPharmaceutics and Biopharmaceutics:Official Journal ofArbeitsgemeinschaft FurPharmazeutische Verfahrenstechnik e.V,119,353–360.doi.org / 10.1016 / j.ejpb.2017.06.029
[0305] Gong,Y.,Soleymani Abyaneh,H.,Drossis,N.,Niederquell,A.,Kuentz,M.,Leroux,J.-C.,de Haan,H.W.,&Gauthier,M.A.(2019).Ultra-sub-stoichiometric“Dynamic”Bioconjugation Reduces Viscosity by Disrupting Immunoglobulin Oligomerization.Biomacromolecules,20(9),3557–3565.doi.org / 10.1021 / acs.biomac.9b00867
[0306] Gormley,A.J.,Yeow,J.,Ng,G.,Conway, .,Boyer,C.,&Chapman,R.(2018).AnOxygen-Tolerant PET-RAFT Polymerization for Screening Structure-ActivityRelationships.Angewandte Chemie(International Ed.in English),57(6),1557–1562.doi.org / 10.1002 / anie.201711044
[0307] Grubbs,R.B.,&Grubbs,R.H.(2017).50th Anniversary Perspective:LivingPolymerization—Emphasizing the Molecule in Macromolecules.Macromolecules,50(18),6979–6997.doi.org / 10.1021 / acs.macromol.7b01440
[0308] Huckaby,J.T.,Jacobs,T.M.,Li,Z.,Perna,R.J.,Wang,A.,Nicely,N.I.,&Lai,S.K.(2020).Structure of an anti-PEG antibody reveals an open ring thatcaptures highly flexible PEG polymers.Communications Chemistry,3(1),1–8.doi.org / 10.1038 / s42004-020-00369-y
[0309] Jerabek-Willemsen,M.,Wienken,C.J.,Braun,D.,Baaske,P.,&Duhr,S.(2011).Molecular Interaction Studies Using Microscale Thermophoresis.Assay and DrugDevelopment Technologies,9(4),342–353.doi.org / 10.1089 / adt.2011.0380
[0310] Kamerzell,T.J.,Pace,A.L.,Li,M.,Danilenko,D.M.,McDowell,M.,Gokarn,Y.R.,&Wang,Y.J.(2013).Polar solvents decrease the viscosity of highconcentration IgG1 solutions through hydrophobic solvation and interaction:Formulation and biocompatibility considerations.Journal of PharmaceuticalSciences,102(4),1182–1193.doi.org / 10.1002 / jps.23453
[0311] Kinnunen,H.M.,Sharma,V.,Contreras-Rojas,L.R.,Yu,Y.,Alleman,C.,Sreedhara,A.,Fischer,S.,Khawli,L.,Yohe,S.T.,Bumbaca,D.,Patapoff,T.W.,Daugherty,A.L.,&Mrsny,R.J.(2015).A novel in vitro method to model the fate ofsubcutaneously administered biopharmaceuticals and associated formulationcomponents.Journal of Controlled Release,214,94–102.doi.org / 10.1016 / j.jconrel.2015.07.016
[0312] Kozma,G.T.,Shimizu,T.,Ishida,T.,&Szebeni,J.(2020).Anti-PEGantibodies:Properties,formation,testing and role in adverse immune reactionsto PEGylated nano-biopharmaceuticals.Advanced Drug Delivery Reviews,154–155,163–175.doi.org / 10.1016 / j.addr.2020.07.024
[0313] Laaser,J.E.,Jiang,Y.,Sprouse,D.,Reineke,T.M.,&Lodge,T.P.(2015).PH-andIonic-Strength-Induced Contraction of Polybasic Micelles in Buffered AqueousSolutions.Macromolecules,48(8),2677–2685.doi.org / 10.1021 / acs.macromol.5b00360
[0314] Ladbury,J.E.,&Chowdhry,B.Z.(1996).Sensing the heat:The application ofisothermal titration calorimetry to thermodynamic studies of biomolecularinteractions.Chemistry&Biology,3(10),791–801.doi.org / 10.1016 / S1074-5521(96)90063-0
[0315] Lee,H.,Son,S.H.,Sharma,R.,&Won,Y.-Y.(2011).A discussion of the pH-dependent protonation behaviors of poly(2-(dimethylamino)ethyl methacrylate)(PDMAEMA)and poly(ethylenimine-ran-2-ethyl-2-oxazoline)(P(EI-r-EOz)).TheJournal of Physical Chemistry.B,115(5),844–860.doi.org / 10.1021 / jp109151s
[0316] Lodge,T.P.,&Muthukumar,M.(1996).Physical chemistry of polymers:Entropy,interactions,and dynamics.Journal of Physical Chemistry,100(31),13275–13292.doi.org / 10.1021 / jp960244z
[0317] Lu,R.-M.,Hwang,Y.-C.,Liu,I.-J.,Lee,C.-C.,Tsai,H.-Z.,Li,H.-J.,&Wu,H.-C.(2020).Development of therapeutic antibodies for the treatment ofdiseases.Journal ofBiomedical Science,27(1),1.doi.org / 10.1186 / s12929-019-0592-z
[0318] Mann,J.L.,Maikawa,C.L.,Smith,A.A.A.,Grosskopf,A.K.,Baker,S.W.,Roth,G.A.,Meis,C.M.,Gale,E.C.,Liong,C.S.,Correa,S.,Chan,D.,Stapleton,L.M.,Yu,A.C.,Muir,B.,Howard,S.,Postma,A.,&Appel,E.A.(2020).An ultrafast insulinformulation enabled by high-throughput screening of engineered polymericexcipients.Science Translational Medicine,12(550),eaba6676.doi.org / 10.1126 / scitranslmed.aba6676
[0319] Matyjaszewski,K.,&Xia,J.(2001).Atom transfer radicalpolymerization.Chemical Reviews,101(9),2921–2990.doi.org / 10.1021 / cr940534g
[0320] Mittal,K.L.(1972).Determination of CMC of polysorbate 20 in aqueoussolution by surface tension method.Journal ofPharmaceutical Sciences,61(8),1334–1335.doi.org / 10.1002 / jps.2600610842
[0321] Ng,G.,Yeow,J.,Chapman,R.,Isahak,N.,Wolvetang,E.,Cooper-White,J.J.,&Boyer,C.(2018).Pushing the Limits of High Throughput PET-RAFTPolymerization.Macromolecules,51(19),7600–7607.doi.org / 10.1021 / acs.macromol.8b01600
[0322] Oliver,S.,Zhao,L.,Gormley,A.J.,Chapman,R.,&Boyer,C.(2019).Living inthe Fast Lane—High Throughput Controlled / Living RadicalPolymerization.Macromolecules,52(1),3–23.doi.org / 10.1021 / acs.macromol.8b01864
[0323] Panganiban,B.,Qiao,B.,Jiang,T.,DelRe,C.,Obadia,M.M.,Nguyen,T.D.,Smith,A.A.A.,Hall,A.,Sit,I.,Crosby,M.G.,Dennis,P.B.,Drockenmuller,E.,Olverade la Cruz,M.,&Xu,T.(2018).Random heteropolymers preserve protein function inforeign environments.Science (New York,N.Y.),359(6381),1239–1243.doi.org / 10.1126 / science.aao0335
[0324] Perrier,S.(2017).50th Anniversary Perspective:RAFT Polymerization—AUser Guide.Macromolecules,50(19),7433–7447.doi.org / 10.1021 / acs.macromol.7b00767
[0325] Pindrus,M.,Shire,S.J.,Kelley,R.F.,Demeule,B.,Wong,R.,Xu,Y.,&Yadav,S.(2015).Solubility Challenges in High Concentration Monoclonal AntibodyFormulations:Relationship with Amino Acid Sequence and IntermolecularInteractions.Molecular Pharmaceutics,12(11),3896–3907.doi.org / 10.1021 / acs.molpharmaceut.5b00336
[0326] Pivot,X.,Gligorov,J.,Müller,V.,Curigliano,G.,Knoop,A.,Verma,S.,Jenkins,V.,Scotto,N.,Osborne,S.,Fallowfield,L.,Fallowfield,L.,Jenkins,V.,Kilkerr,J.,Langridge,C.,Monson,K.,Jakobsen,E.H.,Nielsen,M.H.,Linnet,S.,Knoop,A.,…Verma,S.(2014).Patients’preferences for subcutaneous trastuzumab versusconventional intravenous infusion for the adjuvant treatment of HER2-positiveearly breast cancer:Final analysis of 488 patients in the international,randomized,two-cohort PrefHer study.Annals ofOncology,25(10),1979–1987.doi.org / 10.1093 / annonc / mdu364
[0327] Shire,S.J.,Shahrokh,Z.,&Liu,J.(2004).Challenges in the development ofhigh protein concentration formulations.Journal ofPharmaceutical Sciences,93(6),1390–1402.doi.org / 10.1002 / jps.20079
[0328] Shukla,D.,&Trout,B.L.(2010).Interaction of arginine with proteins andthe mechanism by which it inhibits aggregation.The Journal of PhysicalChemistry.B,114(42),13426–13438.doi.org / 10.1021 / jp108399g
[0329] Stoner,K.L.,Harder,H.,Fallowfield,L.J.,&Jenkins,V.A.(2014).Intravenous versus Subcutaneous Drug Administration.Which Do PatientsPrefer?A Systematic Review.The Patient.doi.org / 10.1007 / s40271-014-0075-y
[0330] Sudrik,C.,Cloutier,T.,Pham,P.,Samra,H.S.,&Trout,B.L.(2017).Preferential interactions of trehalose,L-arginine.HCl and sodium chloridewith therapeutically relevant IgG1 monoclonal antibodies.MAbs,9(7),1155–1168.doi.org / 10.1080 / 19420862.2017.1358328
[0331] Thakral,S.,Thakral,N.K.,&Majumdar,D.K.(2013). A technologyevaluation.Expert Opinion on Drug Delivery,10(1),131–149.doi.org / 10.1517 / 17425247.2013.736962
[0332] Ting,J.M.,Tale,S.,Purchel,A.A.,Jones,S.D.,Widanapathirana,L.,Tolstyka,Z.P.,Guo,L.,Guillaudeu,S.J.,Bates,F.S.,&Reineke,T.M.(2016).High-Throughput Excipient Discovery Enables Oral Delivery of Poorly SolublePharmaceuticals.ACS Central Science,2(10),748–755.doi.org / 10.1021 / acscentsci.6b00268
[0333] van de Weert,M.,&Stella,L.(2011a).Fluorescence quenching and ligandbinding:A critical discussion of a popular methodology.J.Mol.Struct.,998,144–150.doi.org / 10.1016 / j.molstruc.2011.05.023
[0334] Viola,M.,Sequeira,J.,Seica,R.,Veiga,F.,Serra,J.,Sanros,A.C.,&Ribeiro,A.J.(2018).Subcutaneous delivery of monoclonal antibodies:How do we getthere?-PubMed.Journal of Controlled Release:Official Journal of theControlled Release Society,286,301–314.doi.org / doi:10.1016 / j.jconrel.2018.08.001
[0335] Wang,W.,&Roberts,C.J.(2018).Protein aggregation–Mechanisms,detection,and control.International Journal ofPharmaceutics,550(1),251–268.doi.org / 10.1016 / j.ijpharm.2018.08.043
[0336] Zhang,P.,Sun,F.,Liu,S.,&Jiang,S.(2016).Anti-PEG antibodies in theclinic:Current issues and beyond PEGylation.Journal of Controlled Release:Official Journal of the Controlled Release Society,244(Pt B),184–193.doi.org / 10.1016 / j.jconrel.2016.06.040
[0337] Zumbro,E.,&Alexander-Katz,A.(2020).Influence of Binding Site AffinityPatterns on Binding of Multivalent Polymers.ACS Omega,5(19),10774–10781.doi.org / 10.1021 / acsomega.0c00334。
Claims
1. A random polymer library comprising a mixture of polymers, wherein the library comprises polymers comprising at least three monomers selected from: a. Methyl methacrylate (MMA), b. Oligo(ethylene glycol)methyl ether methacrylate (OEGMA), c. isobutyl methacrylate (IBMA) or butyl methacrylate (BMA), and d. a compound of formula I, Formula I: wherein R1 is O or NH, R2 is methyl, ethyl, propyl or butyl, and R3 is NH2 or N(CH3)2 or a guanidinium group, wherein the library comprises polymers ranging from 3 to 20 kDa.
2. The random polymer library of claim 1, wherein the library comprises polymers comprising a monomer of Formula I, wherein the monomer is dimethylaminomethacrylate (DMAEMA), 2-aminoethylmethacrylate, arginine methacrylate, arginine methacrylamide, N-(3-aminopropyl)methacrylamide, N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm), or N-3-(dimethylamino)propylmethacrylamide.
3. A random polymer library according to claim 1 or 2, wherein at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the polymers in the library comprise at least three monomers, or wherein the random polymer library consists essentially of polymers comprising at least three monomers.
4. A random polymer library according to claim 1 or 2, wherein at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the polymers in the library comprise at least four monomers, or wherein the random polymer library consists essentially of polymers comprising at least four monomers.
5. A random polymer library comprising a mixture of polymers, each polymer comprising a mixture of at least three of the following monomers: methyl methacrylate (MMA), oligo(ethylene glycol) methyl ether methacrylate (OEGMA), isobutyl methacrylate (IBMA) and dimethylamino methacrylate (DMAEMA), wherein the library comprises polymers ranging from 3 to 20 kDa.
6. A random polymer library comprising a mixture of polymers, each polymer comprising a mixture of at least three of the following monomers: methyl methacrylate (MMA), oligo(ethylene glycol) methyl ether methacrylate (OEGMA), isobutyl methacrylate (IBMA) and N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm), wherein the library comprises polymers ranging from 3 to 20 kDa.
7. The random polymer library of any one of claims 1 to 6, wherein the library comprises polymers of 3 to 15 kDa, 5 to 20 kDa, 5 to 15 kDa, 5 to 10 kDa, 10 to 20 kDa, 7 to 10 kDa, or 10 to 15 kDa.
8. The random polymer library of any one of claims 1 to 7, wherein the library comprises OEGMA having a molecular weight of 300 g / mol to 1500 g / mol.
9. The random polymer library of claim 8, wherein the OEGMA has a molecular weight of 300, 500, 750, 950, 1000, 1200 or 1500 g / mol.
10. The random polymer library of claim 8, wherein the OEGMA has a molecular weight of 500 g / mol (ie, OEGMA 500).
11. A random polymer library according to any one of claims 1 to 4 or 7 to 10, wherein the library comprises polymers comprising three monomers.
12. A random polymer library according to claim 11, wherein at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the polymers in the library comprise three monomers, or wherein the random polymer library consists essentially of polymers comprising three monomers.
13. The random polymer library according to claim 11 or 12, wherein the three monomers are MMA, OEGMA, and any one of IBMA or BMA. The random polymer library according to claim 13 , wherein the three monomers are MMA, OEGMA and IBMA.
15. The random polymer library of claim 13, wherein the MMA, OEGMA and IBMA or BMA are present in the following ratios: (a) 5:3:2, or (b) 3:5:2, or (c) 5:4:
1.
16. The random polymer library of any one of claims 1 to 10, wherein the library comprises polymers comprising four monomers.
17. A random polymer library according to claim 16, wherein at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the polymers in the library comprise three monomers, or wherein the random polymer library consists essentially of polymers comprising three monomers.
18. The random polymer library according to claim 16 or 17, wherein the four monomers are MMA, OEGMA, IBMA and DMAEMA.
19. The random polymer library of claim 18, wherein the polymer library comprises polymers comprising 20% to 50% MMA, 20% to 50% OEGMA, 5% to 25% IBMA, and 5% to 25% DMAEMA, based on the total weight of the polymer.
20. The random polymer library of claim 18, wherein the polymer library comprises polymers comprising MMA, OEGMA, IBMA, and DMAEMA in the following molar ratios: (a) 5:2.5:2:0.5, (b) 2:5:2:1, (c) 5:2.5:1:1.5, (d) 4:4:1:1; (e) 3:4:1:2, (f) 2:4:1:3; and / or (g) 2:3:1:
4.
21. The random polymer library of claim 18, wherein the MMA, OEGMA, IBMA and DMAEMA are in the following molar ratio: 5:2.5:2:0.5, wherein the OEGMA has a molecular weight of 500 g / mol (i.e., OEGMA 500), wherein the library comprises polymers having a molecular weight of 3 to 15 kDa.
22. The random polymer library according to claim 16 or 17, wherein the four monomers are MMA, OEGMA, IBMA and ArgMAm.
23. The random polymer library of claim 22, wherein the polymer library comprises polymers comprising 20% to 50% MMA, 20% to 50% OEGMA, 5% to 25% IBMA, and 5% to 25% ArgMAm, based on the total weight of the polymer.
24. The random polymer library of claim 22, wherein the polymer library comprises polymers comprising MMA, OEGMA, IBMA, and ArgMAm in the following molar ratios: (a) 5:2.5:2:0.5, (b) 2:5:2:1, (c) 5:2:1:2, (d) 4:4:1:1, (e) 3:4:1:2, (f) 2:4:1:3; and / or (g) 2:3:1:
4.
25. The random polymer library of claim 22, wherein the MMA, OEGMA, IBMA and ArgMAm are in the following molar ratios: 5:2:1:2 or 4:4:1:1, wherein the OEGMA has a molecular weight of 500 g / mol (i.e., OEGMA500), wherein the library comprises polymers having a molecular weight of 3 kDa to 15 kDa.
26. A random polymer library comprising a mixture of polymers, wherein the library comprises polymers comprising at least two monomers selected from the group consisting of oligo(ethylene glycol) methyl ether methacrylate (OEGMA) and either isobutyl methacrylate (IBMA) or butyl methacrylate (BMA), and / or at least two monomers selected from the group consisting of oligo(ethylene glycol) methyl ether methacrylate (OEGMA) and N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm), optionally wherein the OEGMA has a molecular weight of 500 g / mol (i.e., OEGMA 500), and optionally wherein the library comprises polymers having a molecular weight of 3 kDa to 15 kDa.
27. A random polymer comprising a mixture of at least three monomers selected from: a. Methyl methacrylate (MMA), b. Oligo(ethylene glycol)methyl ether methacrylate (OEGMA), c. isobutyl methacrylate (IBMA) or butyl methacrylate (BMA), and d. a compound of formula I, Formula I: wherein R1 is O or NH, R2 is methyl, ethyl, propyl or butyl, and R3 is NH2 or N(CH3)2 or a guanidinium group, wherein the polymer is 3 kDa to 20 kDa.
28. The random polymer of claim 27, wherein the polymer comprises a monomer of formula I, Formula I: The monomer is dimethylaminomethacrylate (DMAEMA), 2-aminoethylmethacrylate, arginine methacrylate, arginine methacrylamide, N-(3-aminopropyl)methacrylamide, N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm) or N-3-(dimethylamino)propylmethacrylamide.
29. A random polymer comprising a mixture of at least three of the following monomers: methyl methacrylate (MMA), oligo(ethylene glycol) methyl ether methacrylate (OEGMA), isobutyl methacrylate (IBMA) and dimethylamino methacrylate (DMAEMA), wherein the polymer is 3 to 20 kDa.
30. A random polymer comprising a mixture of at least three of the following monomers: methyl methacrylate (MMA), oligo(ethylene glycol) methyl ether methacrylate (OEGMA), isobutyl methacrylate (IBMA), and N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm), wherein the polymer is 3 to 20 kDa.
31. The random polymer of any one of claims 27 to 30, wherein the polymer is 3 to 15 kDa, 5 to 20 kDa, 5 to 15 kDa, 5 to 10 kDa, 10 to 20 kDa, 7 to 10 kDa, or 10 to 15 kDa.
32. The random polymer of any one of claims 27 to 31, wherein the polymer comprises OEGMA having a molecular weight of 300 to 1500 g / mol.
33. The random polymer of claim 32, wherein the OEGMA has a molecular weight of 300, 500, 750, 950, 1000, 1200 or 1500 g / mol.
34. The random polymer of claim 33, wherein the OEGMA has a molecular weight of 500 g / mol.
35. The random polymer of any one of claims 27 to 28 or 31 to 34, wherein the polymer comprises three monomers.
36. The random polymer according to claim 35, wherein the three monomers are MMA, OEGMA, and any one of IBMA and BMA.
37. The random polymer of claim 36, wherein the three monomers are MMA, OEGMA and IBMA.
38. The random polymer of claim 37, wherein the MMA, OEGMA, and IBMA or BMA are present in the following ratios: (a) 5:3:2, or (b) 3:5:2, or (c) 5:4:
1.
39. The random polymer of any one of claims 27 to 34, wherein the polymer comprises four monomers.
40. The random polymer of claim 39, wherein the four monomers are MMA, OEGMA, IBMA, and DMAEMA.
41. The random polymer of claim 40, wherein the polymer comprises 20% to 50% MMA, 20% to 50% OEGMA, 5% to 25% IBMA, and 5% to 25% DMAEMA, based on the total weight of the polymer.
42. The random polymer of claim 40, wherein the polymer comprises MMA, OEGMA, IBMA, and DMAEMA in the following molar ratios: (a) 5:2.5:2:0.5, (b) 2:5:2:1, (c) 5:2.5:1:1.5, (d) 4:4:1:1, (e) 3:4:1:2, (f) 2:4:1:3; or (g) 2:3:1:
4.
43. The random polymer of claim 40, wherein the MMA, OEGMA, IBMA and DMAEMA are in the following molar ratio: 5:2.5:2:0.5, wherein the OEGMA is OEGMA 500, wherein the polymer has a molecular weight of 3 to 15 kDa.
44. The random polymer of claim 39, wherein the four monomers are MMA, OEGMA, IBMA, and ArgMAm.
45. The random polymer of claim 44, wherein the polymer comprises 20% to 50% MMA, 20% to 50% OEGMA, 5% to 25% IBMA, and 5% to 25% ArgMAm, based on the total weight of the polymer.
46. The random polymer of claim 44, wherein the polymer comprises MMA, OEGMA, IBMA, and ArgMAm in the following molar ratios: (a) 5:2.5:2:0.5, (b) 2:5:2:1, (c) 5:2.5:1:1.5, (d) 4:4:1:1, (e) 3:4:1:2, (f) 2:4:1:3; or (g) 2:3:1:
4.
47. The random polymer of claim 44, wherein the MMA, OEGMA, IBMA and ArgMAm are in the following molar ratios: 5:2:1:2 or 4:4:1:1, wherein the OEGMA is OEGMA 500, wherein the polymer has a molecular weight of 3 kDa to 15 kDa.
48. A random polymer comprising a mixture of at least two monomers selected from the group consisting of oligo(ethylene glycol) methyl ether methacrylate (OEGMA) and either isobutyl methacrylate (IBMA) or butyl methacrylate (BMA), and / or at least two monomers selected from the group consisting of oligo(ethylene glycol) methyl ether methacrylate (OEGMA) and N-(3-methacrylamidopropyl)guanidine hydrochloride (ArgMAm), optionally wherein the OEGMA has a molecular weight of 500 g / mol (i.e., OEGMA 500), and optionally wherein the polymer has a molecular weight of 3 to 15 kDa.
49. The random polymer of any one of claims 27 to 48, wherein the polymer has a molecular weight of 7 to 10 kDa.
50. A composition comprising a random polymer according to any one of claims 27 to 49, and at least one protein.
51. A composition according to claim 50, wherein the concentration of the polymer is from 0.01% w / v to 1% w / v, such as from 0.01% w / v to 0.1% w / v.
52. The composition of claim 50 or 51, wherein the protein is an antibody.
53. The composition of claim 52, wherein the antibody is an IgG antibody, such as a full length IgG, a bispecific IgG, or wherein the antibody is an antigen binding fragment, such as a Fab, Fab', (Fab')2, Fv or scFv.
54. A composition according to any one of claims 50 to 53, wherein the composition further comprises at least one buffer, such as histidine, phosphate or citrate.
55. A composition according to any one of claims 50 to 54, wherein the composition further comprises at least one surfactant, such as a polysorbate, for example polysorbate 20 or polysorbate 80.
56. according to the composition described in any one of claims 50 to 55, wherein the concentration of the antibody is 10 to 150mg / mL, such as 10 to 100mg / mL, 20 to 100mg / mL, 20 to 80mg / mL, 10 to 50mg / mL, 10 to 25mg / mL, 25 to 50mg / mL, 50 to 80mg / mL, 50 to 100mg / mL or 70 to 100mg / mL.
57. A method of reducing the viscosity of a protein-containing composition and / or inhibiting precipitation of a protein-containing composition, comprising adding a random polymer according to any one of claims 27 to 49 to the composition, optionally wherein the composition comprises a protein and / or an excipient according to any one of claims 50 to 56.
58. A method for preparing a random polymer library according to any one of claims 1 to 26 or a random polymer according to any one of claims 27 to 49, wherein the method comprises reversible addition / fragmentation chain transfer (RAFT), free radical polymerization (FRP) or atom transfer radical polymerization (ATRP).
59. A method for preparing a random polymer library according to any one of claims 1 to 26 or a random polymer according to any one of claims 27 to 49, the method comprising: The monomers are exposed to LED light and / or heat in the presence of zinc tetraphenylporphyrin catalyst (ZnTPP) and a chain transfer agent.
60. The method of claim 59, wherein the chain transfer agent is 2-cyano-2-propyl dithiobenzoate, 2-cyano-2-propyl dodecyl trithiocarbonate, 4-((((2-carboxyethyl)thio)thiocarbonyl)thio)-4-cyanopentanoic acid, 4-cyano-4-(phenylthiocarbonylthio)pentanoic acid, or 4-cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanoic acid (CDTPA).
61. The method of claim 59 or 60, wherein the monomer is exposed to LED light in the presence of the ZnTPP and a chain transfer agent for 3 to 18 hours.
62. The method of any one of claims 59 to 61, wherein polymerisation is terminated by removing the LED lamp.
63. The method of any one of claims 58 to 62, further comprising performing at least one filtration, buffer exchange or dialysis step to isolate the polymer.
64. A kit comprising a random polymer library according to any one of claims 1 to 26 for testing the effect of the polymers included in the library on the precipitation, viscosity and / or turbidity of a solution comprising a protein, the kit optionally further comprising instructions for use.
65. The kit of claim 64, wherein the library comprises at least 10, at least 20, at least 50, or at least 80 different individual random polymers.
66. A method of identifying a random polymer excipient for a protein solution, comprising exposing the protein solution to a random polymer library according to any one of claims 1 to 26 or a kit according to claim 64 or 65, and determining one or more of viscosity, turbidity or precipitation of the solution.
